<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005578.pub2" GROUP_ID="MOVEMENT" ID="752905041411181499" MERGED_FROM="" MODIFIED="2014-10-13 12:18:33 +0100" MODIFIED_BY="Ema Roque" REVIEW_NO="" REVMAN_SUB_VERSION="5.2.7 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2014-10-13 12:16:13 +0100" MODIFIED_BY="Ema Roque">
<TITLE>Pharmacotherapy for sleep bruxism</TITLE>
<CONTACT>
<PERSON ID="62E0491B82E26AA201F801F7BD1071A6" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Cristiane</FIRST_NAME>
<MIDDLE_INITIALS>R</MIDDLE_INITIALS>
<LAST_NAME>Macedo</LAST_NAME>
<SUFFIX/>
<POSITION>Researcher/Trials Search Co-ordinator</POSITION>
<EMAIL_1>crisrufa@uol.com.br</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Brazilian Cochrane Centre</DEPARTMENT>
<ORGANISATION>Centro de Estudos de Saúde Baseada em Evidências e Avaliação Tecnológica em Saúde</ORGANISATION>
<ADDRESS_1>Rua Borges Lagoa, 564 cj 63</ADDRESS_1>
<ADDRESS_2/>
<CITY>São Paulo</CITY>
<ZIP>CEP 04038-000</ZIP>
<REGION>SP</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>55 11 55752970</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2014-10-13 12:16:13 +0100" MODIFIED_BY="Ema Roque">
<PERSON ID="62E0491B82E26AA201F801F7BD1071A6" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Cristiane</FIRST_NAME>
<MIDDLE_INITIALS>R</MIDDLE_INITIALS>
<LAST_NAME>Macedo</LAST_NAME>
<SUFFIX/>
<POSITION>Researcher/Trials Search Co-ordinator</POSITION>
<EMAIL_1>crisrufa@uol.com.br</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Brazilian Cochrane Centre</DEPARTMENT>
<ORGANISATION>Centro de Estudos de Saúde Baseada em Evidências e Avaliação Tecnológica em Saúde</ORGANISATION>
<ADDRESS_1>Rua Borges Lagoa, 564 cj 63</ADDRESS_1>
<ADDRESS_2/>
<CITY>São Paulo</CITY>
<ZIP>CEP 04038-000</ZIP>
<REGION>SP</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>55 11 55752970</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1310041222265506300981425766883" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Elizeu</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Macedo</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>elizeumacedo@uol.com.br</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cognitive Neuroscience Laboratory and Developmental Disorders Program</DEPARTMENT>
<ORGANISATION>Mackenzie Presbyterian University</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>São Paulo</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="01396860867413614443100406040617" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Maria</FIRST_NAME>
<MIDDLE_INITIALS>R</MIDDLE_INITIALS>
<LAST_NAME>Torloni</LAST_NAME>
<SUFFIX>MD,PhD</SUFFIX>
<POSITION>Assistant Director / Coordinator of International Affairs</POSITION>
<EMAIL_1>ginecologia@terra.com.br</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Brazilian Cochrane Centre</DEPARTMENT>
<ORGANISATION>Centro de Estudos de Saúde Baseada em Evidências e Avaliação Tecnológica em Saúde</ORGANISATION>
<ADDRESS_1>Rua Borges Lagoa, 564 cj 63</ADDRESS_1>
<ADDRESS_2/>
<CITY>São Paulo</CITY>
<ZIP>04038-000</ZIP>
<REGION>SP</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>55 11 55752970</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="62E04A3482E26AA201F801F7AABC5550" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Ademir</FIRST_NAME>
<MIDDLE_INITIALS>B</MIDDLE_INITIALS>
<LAST_NAME>Silva</LAST_NAME>
<SUFFIX/>
<POSITION>Neurologist</POSITION>
<EMAIL_1>absilvamd@superig.com.br</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Neurology, Neurosurgery and Neuroscience</DEPARTMENT>
<ORGANISATION>Universidade Federal de São Paulo</ORGANISATION>
<ADDRESS_1>Rua Pedro de Toledo</ADDRESS_1>
<ADDRESS_2>980 conj. 82</ADDRESS_2>
<CITY>São Paulo</CITY>
<ZIP>04039-002</ZIP>
<REGION>São Paulo</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>+55 11 5084 2010</PHONE_1>
<PHONE_2/>
<FAX_1>+55 11 5084 2010</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="38D0FA0C82E26AA201BA4B547DC85853" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Gilmar</FIRST_NAME>
<MIDDLE_INITIALS>F</MIDDLE_INITIALS>
<LAST_NAME>Prado</LAST_NAME>
<SUFFIX/>
<POSITION>Professor</POSITION>
<EMAIL_1>gilmarunifesp@yahoo.com.br</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Neurology</DEPARTMENT>
<ORGANISATION>Escola Paulista de Medicina, Universidade Federal de São Paulo</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>São Paulo</CITY>
<ZIP/>
<REGION>São Paulo</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>+55 11 5081 6629</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2014-10-02 21:56:45 +0100" MODIFIED_BY="Ema Roque">
<UP_TO_DATE>
<DATE DAY="5" MONTH="11" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="15" MONTH="8" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="5" MONTH="10" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="10" YEAR="2014"/>
<LAST_CITATION_ISSUE ISSUE="10" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2013-10-01 21:08:26 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="18" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="13" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Brazilian Cochrane Centre</NAME>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-10-03 13:29:25 +0100" MODIFIED_BY="Anne Lawson">
<SUMMARY MODIFIED="2014-10-03 00:12:24 +0100" MODIFIED_BY="Anne Lawson">
<TITLE MODIFIED="2014-10-02 21:50:20 +0100" MODIFIED_BY="Anne Lawson">Pharmacotherapy for tooth grinding or clenching during the sleep (sleep bruxism)</TITLE>
<SUMMARY_BODY MODIFIED="2014-10-03 00:12:24 +0100" MODIFIED_BY="Anne Lawson">
<P>
<B>Background</B>
</P>
<P>There are several signs and symptoms of sleep bruxism, such as abnormal tooth wear, fractured teeth, jaw muscle discomfort, joint pain or tenderness, and headaches. Treatments include odontological devices such as occlusal splints, psychotherapy and medications (pharmacotherapy). Pharmacological treatments include drugs such as benzodiazepines, anticonvulsants, beta-blockers, dopamine agents, antidepressants, muscle relaxants and others. However, little is known about the effectiveness, safety and long-term follow-up of medications for sleep bruxism.</P>
<P>
<B>Study characteristics</B>
</P>
<P>We searched scientific databases for clinical trials comparing any drug with placebo (a dummy treatment), other drugs or no treatment in people of any age with sleep bruxism. The evidence is current to August 2014.</P>
<P>
<B>Key results</B>
</P>
<P>A total of 18 studies were identified and seven were included in the review. Each individual study involved a very small number of participants (7-16) and four of them were of moderate methodological quality. Amitriptyline (three studies), bromocriptine (one study), clonidine (one study), propranolol (one study), levodopa (Prolopa®) (one study) and tryptophan (one study) were compared with placebo. Amitriptyline and L-tryptophan did not reduce activity of the jaw muscles, measured using electromyography. Bromocriptine,clonidine, propanolol and levodopa did not significantly reduce the number of bruxism episodes per hour when compared to placebo.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>This systematic review concluded that there is not enough evidence in the literature to show that drugs can reduce sleep bruxism.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-10-02 21:50:20 +0100" MODIFIED_BY="Anne Lawson">
<ABS_BACKGROUND MODIFIED="2014-10-02 21:50:20 +0100" MODIFIED_BY="Anne Lawson">
<P>Sleep bruxism is an oral activity characterized by involuntary teeth grinding or clenching during sleep. Several forms of treatment have been proposed for this disorder, including behavioural, dental and pharmacological strategies.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-10-02 21:00:09 +0100" MODIFIED_BY="Anne Lawson">
<P>To evaluate the effectiveness and safety of pharmacological therapy for the treatment of sleep bruxism compared with other drugs, no treatment or placebo.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-10-02 21:00:08 +0100" MODIFIED_BY="Anne Lawson">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 8, 2014), MEDLINE (1966 to August 2014), EMBASE (1980 to August 2013) and LILACS (1982 to August 2014). We identified additional reports from the reference lists of retrieved reports and from reviews on treatment of sleep bruxism. We applied no language restrictions.<BR/>
</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-10-02 21:50:20 +0100" MODIFIED_BY="Anne Lawson">
<P>We selected randomized controlled trials (RCTs) or quasi-RCTs that compared drugs with other drugs, no treatment or placebo in people with sleep bruxism.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-10-02 21:50:20 +0100" MODIFIED_BY="Anne Lawson">
<P>Review authors carried out data extraction and quality assessment of the included trials independently and in duplicate. We discussed discrepancies until we reached consensus. We consulted a third review author in cases of persistent disagreement. We contacted authors of primary studies when necessary.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-10-02 21:50:20 +0100" MODIFIED_BY="Anne Lawson">
<P>We identified 18 potentially relevant RCTs, but only seven met the inclusion criteria. All studies had a small number of participants, ranging from seven to 16 people per study and had a cross-over design. Three studies were of low risk of bias, while four were of uncertain risk. Amitriptyline (three studies), bromocriptine (one study), clonidine (one study), propranolol (one study), levodopa (Prolopa®) (one study) and tryptophan (one study) were compared with placebo. Studies evaluating bromocriptine, clonidine, propranolol and levodopa reported our primary outcome of indices of bruxism motor activity.</P>
<P>Results were imprecise and consistent with benefit, no difference or harm. These were the specific findings for each of the drugs according to specific outcomes: 1. Amitriptyline versus placebo for masseteric electromyography (EMG) activity per minute: standardized mean difference (SMD) -0.28 (95% confidence interval (CI) -0.91 to 0.34; P value = 0.37), 2. bromocriptine versus placebo for bruxism episodes per hour: mean difference (MD) 0.60 (95% CI -2.93 to 4.13), bruxism bursts per hour: MD -2.00 (95% CI -53.47 to 49.47), bruxism bursts per episode: MD 0.50 (95% CI -1.85 to 2.85) or number of episodes with grinding noise: MD 2.40 (95% CI -24.00 to 28.80), 3. clonidine versus placebo for number of bruxism episodes per hour: MD -2.41 (95% CI -4.84 to 0.02), 4. propranolol versus placebo for the number of bruxism episodes per hour: MD 1.16 (95% CI -1.89 to 4.21), 5. L-tryptophan versus placebo for masseteric EMG activity per second: SMD 0.08 (95% CI -0.90 to 1.06) and 6. levodopa versus placebo for bruxism episodes per hour of sleep: MD -1.47 (95% CI -3.64 to 0.70), for bruxism bursts per episode: MD 0.06 (95% CI -2.47 to 2.59).</P>
<P>We combined several secondary outcomes (sleep duration, masseteric EMG activity per minute and pain intensity) in a meta-analysis for comparison of amitriptyline with placebo. The results for most comparisons were uncertain because of statistical imprecision<I>.</I> One study reported that clonidine reduced rapid eye movement (REM) sleep stage and increased the second stage of sleep. However, results for other sleep-related outcomes with clonidine were uncertain. Adverse effects were frequent in people who took amitriptyline (5/10 had drowsiness, difficulty awakening in the morning, insomnia or xerostomia compared with 0/10 in the placebo group), as well as in people who received propranolol (7/16 had moderate-to-severe xerostomia compare with 2/16 in the placebo group). Clonidine was associated with prolonged morning hypotension in three of 16 participants. The use of preventive medication avoided any adverse effects in people treated with levodopa and bromocriptine.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-10-02 21:50:20 +0100" MODIFIED_BY="Anne Lawson">
<P>There was insufficient evidence on the effectiveness of pharmacotherapy for the treatment of sleep bruxism. This systematic review points to the need for more, well-designed, RCTs with larger sample sizes and adequate methods of allocation, outcome assessment and duration of follow-up. Ideally, parallel RCTs should be used in future studies to avoid the bias associated with cross-over studies. There is a need to standardize the outcomes of RCTs on treatments for sleep bruxism.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-10-03 13:15:25 +0100" MODIFIED_BY="Anne Lawson">
<BACKGROUND MODIFIED="2014-10-02 21:50:21 +0100" MODIFIED_BY="Anne Lawson">
<P>The term bruxism, which originates from the Greek "brychein" meaning tooth grinding (<LINK REF="REF-Dorland-1994" TYPE="REFERENCE">Dorland 1994</LINK>), was first introduced in 1931 by Frohman (<LINK REF="REF-Faulkner-1990" TYPE="REFERENCE">Faulkner 1990</LINK>).</P>
<P>Bruxism can be classified into primary (idiopathic) versus secondary (iatrogenic) forms, and daytime-awake versus sleep bruxism (<LINK REF="REF-de-la-Hoz_x002d_Aizpurua-2011" TYPE="REFERENCE">de la Hoz-Aizpurua 2011</LINK>; <LINK REF="REF-Lavigne-2008" TYPE="REFERENCE">Lavigne 2008</LINK>). Primary bruxism is unrelated to any other medical condition, while secondary bruxism is associated with medical conditions (e.g. neurological, psychiatric or sleep disorders) or the use of medications for their treatment. Sleep bruxism is a sleep-related movement disorder characterized by grinding or clenching of the teeth during sleep (<LINK REF="REF-AASD-2005" TYPE="REFERENCE">AASD 2005</LINK>). Individuals with sleep bruxism have tooth grinding due to involuntary jaw muscle contractions that can be phasic (rhythmic), tonic (sustained) or mixed (both types) (<LINK REF="REF-Barder-2000" TYPE="REFERENCE">Barder 2000</LINK>). Bruxism can also occur when awake, as semi-voluntary clenching activity of the jaw rarely associated with sounds. This latter condition is a completely different disorder thought to be mainly related to stress or anxiety expressed as a jaw muscle clenching habit or tic (<LINK REF="REF-Lavigne-2005" TYPE="REFERENCE">Lavigne 2005</LINK>). However, up to one-third of people with sleep bruxism may also have daytime bruxism (<LINK REF="REF-Carlsson-2003" TYPE="REFERENCE">Carlsson 2003</LINK>; <LINK REF="REF-Carra-2012" TYPE="REFERENCE">Carra 2012</LINK>).</P>
<CONDITION MODIFIED="2014-10-02 21:50:20 +0100" MODIFIED_BY="Anne Lawson">
<P>The International Classification of Sleep Disorders (ICSD)-2 categorizes sleep bruxism as a sleep-related movement disorder, not as parasomnia (<LINK REF="REF-AASD-2005" TYPE="REFERENCE">AASD 2005</LINK>). Sleep-related bruxism is usually associated with sleep arousals (<LINK REF="REF-AASD-2005" TYPE="REFERENCE">AASD 2005</LINK>), and accompanied by sounds (<LINK REF="REF-Barder-2000" TYPE="REFERENCE">Barder 2000</LINK>).</P>
<P>During sleep, orofacial activities including coughing, swallowing, sleep talking, smiling, lip sucking and jaw movements are common (<LINK REF="REF-Kato-2001" TYPE="REFERENCE">Kato 2001</LINK>). Sleep bruxism may be an extreme manifestation of a physiological orofacial motor behaviour during sleep (<LINK REF="REF-Carra-2012" TYPE="REFERENCE">Carra 2012</LINK>).</P>
<P>Sleep bruxism can lead to abnormal tooth wear, fractured teeth, tongue indentation, polygraphic observation of jaw muscle activity with audible teeth grinding sounds, masseter muscle hypertrophy, reduction in salivary flow, lip or cheek biting and burning tongue with concomitant oral habits (<LINK REF="REF-Barder-2000" TYPE="REFERENCE">Barder 2000</LINK>). Symptoms include tooth grinding sounds during sleep, as related by a person's partner, jaw muscle discomfort with or without pain, temporomandibular joint tenderness or pain on digital palpation, facial pain, headache and tooth hypersensitivity. Stress and anxiety are also commonly noted in people with sleep bruxism (<LINK REF="REF-AASD-2005" TYPE="REFERENCE">AASD 2005</LINK>). Severe sleep-related bruxism may also result in sleep disruption, which has implications not only for the person but also for the bed partner, because the sounds resulting from tooth friction are usually perceived as being unpleasant and can be loud and disturbing (<LINK REF="REF-Ferini_x002d_Strambi-2011" TYPE="REFERENCE">Ferini-Strambi 2011</LINK>).</P>
<P>Sleep bruxism is very frequent in early life and decreases with advancing age. This disorder affects 14% to 20% of all children (<LINK REF="REF-Abe-1966" TYPE="REFERENCE">Abe 1966</LINK>; <LINK REF="REF-Widmalm-1995" TYPE="REFERENCE">Widmalm 1995</LINK>), and 13% of people aged 18 to 29 years (<LINK REF="REF-Partinen-1994" TYPE="REFERENCE">Partinen 1994</LINK>). Approximately 8% of adults have at least one weekly episode of tooth grinding during sleep (<LINK REF="REF-Lavigne-1994" TYPE="REFERENCE">Lavigne 1994</LINK>), while less than 3% of people over 60 years of age have sleep bruxism (<LINK REF="REF-Ohayon-2001" TYPE="REFERENCE">Ohayon 2001</LINK>). There are no reported gender differences in the prevalence of sleep bruxism (<LINK REF="REF-Glacos-1981" TYPE="REFERENCE">Glacos 1981</LINK>; <LINK REF="REF-Lavigne-1994" TYPE="REFERENCE">Lavigne 1994</LINK>; <LINK REF="REF-Melis-2003" TYPE="REFERENCE">Melis 2003</LINK>).</P>
<P>Several risk factors have been linked to sleep-related bruxism including tobacco, drugs, alcohol, psychiatric disorders, sleep disorders (e.g. sleep apnoea, restless legs), respiratory disturbances and anxiety (<LINK REF="REF-Lavigne-1997" TYPE="REFERENCE">Lavigne 1997</LINK>; <LINK REF="REF-Ohayon-2001" TYPE="REFERENCE">Ohayon 2001</LINK>). Although stress, anxiety and personality disorders have been associated with sleep bruxism, their roles and influences are unclear (<LINK REF="REF-Lobbezoo-2001" TYPE="REFERENCE">Lobbezoo 2001</LINK>; <LINK REF="REF-Ohayon-2001" TYPE="REFERENCE">Ohayon 2001</LINK>). Although no genetic markers have been identified to date, 21% to 50% of people who grind their teeth while asleep have a direct family member who ground his or her teeth in childhood (<LINK REF="REF-Abe-1966" TYPE="REFERENCE">Abe 1966</LINK>).</P>
<P>The exact causes and pathophysiology of sleep bruxism are still unclear (<LINK REF="REF-Lavigne-2007" TYPE="REFERENCE">Lavigne 2007</LINK>). Several aetiological mechanisms for sleep bruxism have been proposed, including sleep arousal, autonomic sympathetic-cardiac activation, genetic predisposition, neurochemical factors, psychosocial components, exogenous factors and co-morbidities (<LINK REF="REF-Carra-2012" TYPE="REFERENCE">Carra 2012</LINK>; <LINK REF="REF-Lavigne-2007" TYPE="REFERENCE">Lavigne 2007</LINK>; <LINK REF="REF-Lobbezoo-2001" TYPE="REFERENCE">Lobbezoo 2001</LINK>). Disturbances in the central dopaminergic system may be involved in the aetiology of sleep bruxism (<LINK REF="REF-Lobbezoo-1996" TYPE="REFERENCE">Lobbezoo 1996</LINK>), and this could explain the appearance of tooth grinding in people taking levodopa (L-dopa) for Parkinson's disease (<LINK REF="REF-Magee-1970" TYPE="REFERENCE">Magee 1970</LINK>). Another mechanism includes rhythmic masticatory muscle activity (RMMA), which is commonly found in healthy people, but more frequent and intense in sleep bruxism and is associated with sleep micro-arousal (<LINK REF="REF-Kato-2003" TYPE="REFERENCE">Kato 2003</LINK>).</P>
<P>Diagnosis of sleep bruxism can be challenging. Clinical diagnosis is based on the presence of abnormal tooth wear, jaw muscle discomfort (fatigue or pain), jaw lock upon awakening and masseter muscle hypertrophy (<LINK REF="REF-AASD-2005" TYPE="REFERENCE">AASD 2005</LINK>). However, only an electromyography (EMG) recording of the masticatory muscles can confirm the diagnosis of sleep bruxism (<LINK REF="REF-Carra-2012" TYPE="REFERENCE">Carra 2012</LINK>; <LINK REF="REF-Lavigne-1996" TYPE="REFERENCE">Lavigne 1996</LINK>). Polysomnography (PSG) is useful in the differential diagnosis of sleep bruxism from other disorders such as obstructive sleep apnoea, periodic leg movements and rapid eye movement (REM) sleep behaviour disorders (<LINK REF="REF-Lavigne-2005" TYPE="REFERENCE">Lavigne 2005</LINK>). The gold standard for the diagnosis of sleep bruxism remains a full-night PSG with audio-video recording (<LINK REF="REF-Carra-2012" TYPE="REFERENCE">Carra 2012</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2014-10-02 21:50:21 +0100" MODIFIED_BY="Anne Lawson">
<P>Currently, there is no a specific strategy, unique treatment or cure for sleep bruxism. Available treatments aim to manage and prevent the harmful consequences of sleep bruxism. Owing to the multifactorial character of the disorder, many treatments for sleep bruxism have been proposed including behavioural therapy, oral appliances and pharmacotherapy. Benzodiazepines, clonidine, anticonvulsants, beta-blockers, dopamine agents, antidepressants, muscle relaxants and other drugs have been tested in the treatment of sleep bruxism (<LINK REF="REF-Winocur-2003" TYPE="REFERENCE">Winocur 2003</LINK>). Some people with severe bruxism have also received local injections of botulinum toxin (BTX type A) for the relief of their symptoms (<LINK REF="STD-Tan-2000" TYPE="STUDY">Tan 2000</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2014-10-02 21:50:21 +0100" MODIFIED_BY="Anne Lawson">
<P>Pharmacological agents improve bruxism through different mechanisms (<LINK REF="REF-Winocur-2003" TYPE="REFERENCE">Winocur 2003</LINK>). Several medications and drugs that act on the central nervous system have been associated with decreased involuntary orofacial muscle activity during sleep, supporting the probable involvement of the brain in the genesis of sleep bruxism (<LINK REF="REF-Carra-2012" TYPE="REFERENCE">Carra 2012</LINK>; <LINK REF="REF-Lavigne-2008" TYPE="REFERENCE">Lavigne 2008</LINK>). Benzodiazepines have hypnotic, anxiolytic, anticonvulsive and myorelaxant effects. These drugs are thought to improve sleep bruxism due to their actions on different systems linked to muscle activity and emotions (<LINK REF="STD-Salute-2005" TYPE="STUDY">Salute 2005</LINK>; <LINK REF="STD-Saletu-2010" TYPE="STUDY">Saletu 2010</LINK>). Clonidine is an alpha<SUB>2</SUB>-adrenergic agonist that has been shown to reduce sleep bruxism significantly; however, its use is controversial due to important adverse effects as morning hypotension and mouth dryness. (<LINK REF="STD-Carra-2010" TYPE="STUDY">Carra 2010</LINK>; <LINK REF="STD-Huynh--2006" TYPE="STUDY">Huynh 2006</LINK>).</P>
<P>Pharmacological agents can help control sleep bruxism and may be used as part of a multidisciplinary approach, especially at the start of treatment or during periods of exacerbation caused by increased emotional tension (<LINK REF="REF-Carra-2012" TYPE="REFERENCE">Carra 2012</LINK>; <LINK REF="REF-de-la-Hoz_x002d_Aizpurua-2011" TYPE="REFERENCE">de la Hoz-Aizpurua 2011</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2014-10-02 21:50:21 +0100" MODIFIED_BY="Anne Lawson">
<P>Little is known about the effectiveness, safety and long-term follow-up of pharmacological therapy for sleep bruxism (<LINK REF="REF-Lavigne-2005" TYPE="REFERENCE">Lavigne 2005</LINK>). The results of existing trials are controversial. A systematic review of the literature is important to appraise and synthesize the current evidence critically on the effectiveness and safety of drugs used to treat sleep bruxism and help healthcare professionals and people make better decisions regarding treatment.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-10-02 21:50:21 +0100" MODIFIED_BY="Anne Lawson">
<P>To evaluate the effectiveness and safety of pharmacological therapy for the treatment of sleep bruxism compared with other drugs, no treatment or placebo.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-10-02 21:50:22 +0100" MODIFIED_BY="Anne Lawson">
<SELECTION_CRITERIA MODIFIED="2014-10-02 21:50:21 +0100" MODIFIED_BY="Anne Lawson">
<CRIT_STUDIES MODIFIED="2014-10-02 21:50:21 +0100" MODIFIED_BY="Anne Lawson">
<P>Randomized controlled trials (RCTs) comparing any drug with placebo, other drugs or no treatment. We included quasi-randomized trials and subjected them to sensitivity analysis.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-10-02 21:50:21 +0100" MODIFIED_BY="Anne Lawson">
<SUBSECTION>
<HEADING LEVEL="4">Inclusion criteria</HEADING>
<P>Participants of any age with a clinical or PSG (or both) diagnosis of sleep bruxism.</P>
<SUBSECTION>
<HEADING LEVEL="5">Clinical diagnosis according to the International Classification of Sleep Disorders-2</HEADING>
<P>The participant reported or was aware of tooth grinding or clenching during sleep and one or more of the following:</P>
<OL>
<LI>abnormal tooth wear;</LI>
<LI>jaw muscle discomfort, fatigue or pain and jaw lock upon awakening;</LI>
<LI>masseter muscle hypertrophy evident on voluntary forceful clenching.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Polysomnographic diagnosis according to the International Classification of Sleep Disorders-2</HEADING>
<OL>
<LI>PSG monitoring demonstrates jaw muscle activity during the sleep period and absence of associated epileptic activity.</LI>
<LI>PSG diagnostic cut-off criteria:</LI>
<OL>
<LI>more than four bruxism episodes per hour;</LI>
<LI>more than six bruxism bursts per episode or 25 bruxism bursts per hour of sleep, or both; and</LI>
<LI>at least two episodes with grinding sounds (<LINK REF="REF-Lavigne-1996" TYPE="REFERENCE">Lavigne 1996</LINK>).</LI>
</OL>
</OL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Exclusion criteria</HEADING>
<P>We excluded people with co-morbidities, such as neurological and psychiatric diseases, or taking medications known to be associated with sleep bruxism, such as antipsychotic drugs or amphetamines.<BR/>
</P>
</SUBSECTION>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-10-02 21:50:21 +0100" MODIFIED_BY="Anne Lawson">
<P>Any drug compared with:</P>
<OL>
<LI>placebo;</LI>
<LI>no treatment;</LI>
<LI>other drugs: such as sedative, muscle relaxant, serotonin related, dopaminergic related, cardioactive and BTX.</LI>
</OL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-10-02 21:50:21 +0100" MODIFIED_BY="Anne Lawson">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-10-02 21:50:21 +0100" MODIFIED_BY="Anne Lawson">
<OL>
<LI>Indexes of bruxism motor activity demonstrated by EMG of the masseter muscle associated with PSG audio-video recordings: frequency of sleep bruxism episodes per hour of sleep (at least four episodes) and number of episodes with grinding noise (minimum of two).</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-10-02 21:50:21 +0100" MODIFIED_BY="Anne Lawson">
<OL>
<LI>Tooth wear.</LI>
<LI>Tooth restoration failure.</LI>
<LI>Quality of life.</LI>
<LI>Adherence.</LI>
<LI>Adverse events.</LI>
<LI>Temporomandibular joint pain.</LI>
<LI>Clicking.</LI>
<LI>Jaw movement limitation.</LI>
<LI>Myofacial pain.</LI>
<LI>Headaches.</LI>
<LI>Sleep variables: REM sleep latency, efficiency, arousals index, stages, sleep latency, wake after sleep onset, total sleep time.</LI>
<LI>Masseteric EMG activity.</LI>
<LI>Apnoea-hypopnoea index.</LI>
</OL>
<P>We considered outcomes regardless of the time of assessment. We considered a subgroup analyses by time of assessment: short term (up to four weeks) and long term (more than four weeks).</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-10-02 21:50:21 +0100" MODIFIED_BY="Anne Lawson">
<P>We used the search methods of the <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/MOVEMENT/sect0-meta.html">Cochrane Movement Disorders Group</A>.<BR/>We searched studies independently of language and source of information.</P>
<ELECTRONIC_SEARCHES MODIFIED="2014-10-02 21:50:21 +0100" MODIFIED_BY="Anne Lawson">
<P>For the identification of studies to be included in or considered for this review, we developed detailed search strategies for each database. We based these on the search strategy developed for MEDLINE via Ovid presented in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>, and revised them appropriately for each database to take into account differences in controlled vocabulary and syntax rules. We combined the search strategy for MEDLINE with the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomized trials in MEDLINE: sensitivity maximising version (2008 revision) as detailed the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>).</P>
<P>We searched the following databases:</P>
<UL>
<LI>the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 8, 2014);</LI>
<LI>MEDLINE (1966 to August 2014);</LI>
<LI>EMBASE (1980 to August 2013);</LI>
<LI>LILACS (1982 to August 2014).</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="4">Cross-checking references</HEADING>
<P>We checked the references from original papers and abstracts, reviews, systematic reviews and meta-analyses to identify any additional studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Personal communications</HEADING>
<P>We contacted the authors of the included studies to ask if they had, or knew of, any relevant unpublished material.</P>
</SUBSECTION>
</ELECTRONIC_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-10-02 21:50:22 +0100" MODIFIED_BY="Anne Lawson">
<STUDY_SELECTION MODIFIED="2014-10-02 21:50:21 +0100" MODIFIED_BY="Anne Lawson">
<P>We assessed all potentially relevant articles and reports using a previously prepared inclusion criteria form. Two review authors (CRM, MRT initially assessed the relevance of each article independently and in duplicate. Citation information was not masked. We resolved disagreements by consulting a third review author (ECM or ABS). We contacted the authors of trial reports for additional information if necessary.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-10-02 21:50:21 +0100" MODIFIED_BY="Anne Lawson">
<P>Two review authors (CRM, MRT) independently extracted data using a specially designed data extraction form based the recommendations in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>). In case of discrepancy, we consulted a third review author (ECM or ABS) for further discussion and reliability. We annotated characteristics of the trial participants, interventions and outcomes for the included trials in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table. We contacted authors for clarification or for further information. For studies with more than one publication, we used the main trial report as a reference and derived additional details from secondary papers.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-10-02 21:50:21 +0100" MODIFIED_BY="Anne Lawson">
<P>In this updated version of the review, two review authors assessed independently and in duplicate the risk of bias in included studies using the 'Risk of bias' tool described in the <I>Cochrane Handbook for Systematic Reviews of interventions </I>(<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>). We investigated the following domains:</P>
<UL>
<LI>sequence generation;</LI>
<LI>allocation concealment;</LI>
<LI>blinding of participants;</LI>
<LI>blinding of outcome assessment;</LI>
<LI>incomplete outcome data addressed;</LI>
<LI>selective outcome reporting.</LI>
</UL>
<P>We classified each domain as having 'low risk of bias', 'high risk of bias' or 'unclear risk of bias'.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2014-10-02 21:50:21 +0100" MODIFIED_BY="Anne Lawson">
<P>For dichotomous outcomes, we expressed the estimate of effect of an intervention as risk ratio (RR) together with its 95% confidence intervals (CI). For continuous outcomes, we used mean difference (MD) or standardized mean difference (SMD) to compare groups and used standard deviations (SD) to summarize the data for each group. We presented estimates of effects with 95% CIs.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2014-10-02 21:50:21 +0100" MODIFIED_BY="Anne Lawson">
<P>For cross-over trials, we included all participants who received all interventions in sequence. For studies with three or more interventions groups, we followed the recommendations of the <I>Cochrane Handbook for Systematic Reviews </I>(<LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>). Consequently, in multiple pair-wise comparisons between all possible pairs of intervention groups, we included the same group of participants only once in the meta-analysis. In the future updates, the unit of analysis could be the individual participant (unit to be randomized for interventions to be compared).</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2014-10-02 21:50:21 +0100" MODIFIED_BY="Anne Lawson">
<P>As far as possible, we analysed data on an intention-to-treat basis. In studies with missing data, we tried to contact the study authors. If this proved unsuccessful, we performed analyses using only available data.</P>
<P>We assessed the number needed to treat for an additional beneficial outcome (NNTB) or harmful outcome (NNTH) and numbers of drop-outs.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2014-10-02 21:50:21 +0100" MODIFIED_BY="Anne Lawson">
<P>We assessed clinical heterogeneity by examining the types of participants, interventions and outcomes in each study. We performed meta-analyses only when studies were of similar comparisons reporting comparable outcome measures in similar participants. We assessed statistical heterogeneity using the I<SUP>2 </SUP>statistic and the Chi<SUP>2</SUP> test with P value &lt; 0.01 indicating significant heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2014-10-02 21:50:22 +0100" MODIFIED_BY="Anne Lawson">
<P>We planned to use a funnel plot (trial effect versus trial size) to explore the possibility of publication bias if we had found sufficient studies (10 or more) for any of the primary analyses.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-10-02 21:50:22 +0100" MODIFIED_BY="Anne Lawson">
<P>For clinically homogeneous studies, we pooled outcomes in meta-analyses using the fixed-effect model as a default and the inverse-variance method.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2014-10-02 21:50:22 +0100" MODIFIED_BY="Anne Lawson">
<P>In future updates, if a sufficient number of studies (more than 10) are eligible, we will perform subgroup analyses according to age, gender, length of treatment and follow-up. We will categorize periods of treatment of the studies as short term (up to four weeks) and long term (more than four weeks).</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2014-10-02 21:50:22 +0100" MODIFIED_BY="Anne Lawson">
<P>We had planned sensitivity analyses for the primary outcomes, if a sufficient number of studies (at least 10) had been identified, to examine the effect of adequate randomization, allocation concealment and blind outcome assessment on the overall estimates of effect.</P>
<P>If we had found an adequate number of studies, we had planned to perform a sensitivity analysis with quasi-randomized studies separately from the RCTs.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-10-02 21:50:22 +0100" MODIFIED_BY="Anne Lawson">
<STUDY_DESCRIPTION MODIFIED="2014-10-02 21:50:22 +0100" MODIFIED_BY="Anne Lawson">
<SEARCH_RESULTS MODIFIED="2014-10-02 21:50:22 +0100" MODIFIED_BY="Anne Lawson">
<P>The 2014 search retrieved 388 citations. After screening the titles and abstracts of these citations, we selected 18 citations for full-text reading, of which we excluded eight, considered three as awaiting classification and included seven that fulfilled our selection criteria (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> for details of the process of study selection). We contacted the authors of seven studies to obtain more details on study characteristics and methodological quality that were unclear in the articles. Only three study authors answered our enquiries (<LINK REF="STD-Huynh--2006" TYPE="STUDY">Huynh 2006</LINK>; <LINK REF="STD-Lavigne-2001" TYPE="STUDY">Lavigne 2001</LINK>; <LINK REF="STD-Lobbezoo-1997a" TYPE="STUDY">Lobbezoo 1997a</LINK>). See the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> tables.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-10-02 21:50:22 +0100" MODIFIED_BY="Anne Lawson">
<P>We identified 18 potentially relevant RCTs, but only seven met the inclusion criteria (<LINK REF="STD-Etzel-1991" TYPE="STUDY">Etzel 1991</LINK>; <LINK REF="STD-Huynh--2006" TYPE="STUDY">Huynh 2006</LINK>; <LINK REF="STD-Lavigne-2001" TYPE="STUDY">Lavigne 2001</LINK>; <LINK REF="STD-Lobbezoo-1997a" TYPE="STUDY">Lobbezoo 1997a</LINK>; <LINK REF="STD-Mohamed-1997" TYPE="STUDY">Mohamed 1997</LINK>; <LINK REF="STD-Raigrodski-2001a" TYPE="STUDY">Raigrodski 2001a</LINK>; <LINK REF="STD-Raigrodski-2001b" TYPE="STUDY">Raigrodski 2001b</LINK>). Two studies were published as congress abstracts and as papers with full results (<LINK REF="STD-Huynh--2006" TYPE="STUDY">Huynh 2006</LINK>; <LINK REF="STD-Lobbezoo-1997a" TYPE="STUDY">Lobbezoo 1997a</LINK>).</P>
<P>All studies included adults aged 18 years or older. Most participants were women (70%), and in two studies there were no men (<LINK REF="STD-Raigrodski-2001a" TYPE="STUDY">Raigrodski 2001a</LINK>; <LINK REF="STD-Raigrodski-2001b" TYPE="STUDY">Raigrodski 2001b</LINK>).</P>
<P>In three studies, there was PSG confirmation of sleep bruxism (<LINK REF="STD-Huynh--2006" TYPE="STUDY">Huynh 2006</LINK>; <LINK REF="STD-Lavigne-2001" TYPE="STUDY">Lavigne 2001</LINK>; <LINK REF="STD-Lobbezoo-1997a" TYPE="STUDY">Lobbezoo 1997a</LINK>), while in the other four studies, the diagnosis was only clinical (<LINK REF="STD-Etzel-1991" TYPE="STUDY">Etzel 1991</LINK>; <LINK REF="STD-Mohamed-1997" TYPE="STUDY">Mohamed 1997</LINK>; <LINK REF="STD-Raigrodski-2001a" TYPE="STUDY">Raigrodski 2001a</LINK>; <LINK REF="STD-Raigrodski-2001b" TYPE="STUDY">Raigrodski 2001b</LINK>).</P>
<P>All included studies were randomized and controlled, with a cross-over design.</P>
<P>Five studies were conducted for a period of eight days to four weeks (<LINK REF="STD-Etzel-1991" TYPE="STUDY">Etzel 1991</LINK>; <LINK REF="STD-Lavigne-2001" TYPE="STUDY">Lavigne 2001</LINK>; <LINK REF="STD-Mohamed-1997" TYPE="STUDY">Mohamed 1997</LINK>; <LINK REF="STD-Raigrodski-2001a" TYPE="STUDY">Raigrodski 2001a</LINK>; <LINK REF="STD-Raigrodski-2001b" TYPE="STUDY">Raigrodski 2001b</LINK>). Only two studies administrated active and inactive medications over two nights (<LINK REF="STD-Huynh--2006" TYPE="STUDY">Huynh 2006</LINK>; <LINK REF="STD-Lobbezoo-1997a" TYPE="STUDY">Lobbezoo 1997a</LINK>). Three studies included a washout period (<LINK REF="STD-Etzel-1991" TYPE="STUDY">Etzel 1991</LINK>; <LINK REF="STD-Lavigne-2001" TYPE="STUDY">Lavigne 2001</LINK>; <LINK REF="STD-Mohamed-1997" TYPE="STUDY">Mohamed 1997</LINK>).</P>
<P>One study compared L-tryptophan with placebo (<LINK REF="STD-Etzel-1991" TYPE="STUDY">Etzel 1991</LINK>). Participants were given either L-tryptophan (50 mg/kg bodyweight) or placebo (lactose) for eight days followed by an eight-day washout period. One study compared propranolol and clonidine with placebo (<LINK REF="STD-Huynh--2006" TYPE="STUDY">Huynh 2006</LINK>). Three studies compared amitriptyline with placebo (<LINK REF="STD-Mohamed-1997" TYPE="STUDY">Mohamed 1997</LINK>; <LINK REF="STD-Raigrodski-2001a" TYPE="STUDY">Raigrodski 2001a</LINK>; <LINK REF="STD-Raigrodski-2001b" TYPE="STUDY">Raigrodski 2001b</LINK>). One study compared bromocriptine with placebo (<LINK REF="STD-Lavigne-2001" TYPE="STUDY">Lavigne 2001</LINK>). To give the participant time to adapt to the medication, each person was started on a lower drug dosage of bromocriptine (1.25 mg), which was increased to the maximum dose of bromocriptine (7.5 mg) or placebo within the first six days and then the dose of bromocriptine or placebo was kept steady for the next eight days. The medication was taken one hour before going to bed, and domperidone 20 mg was administered orally 30 minutes before both interventions to reduce adverse effects. Interventions were administered for two weeks each. There was a one-week washout period. One study compared levodopa with placebo (<LINK REF="STD-Lobbezoo-1997a" TYPE="STUDY">Lobbezoo 1997a</LINK>). Two oral doses of levodopa 100 mg and benserazide 25 mg or placebo were given to the participants: the first dose one hour before bedtime and the second dose four hour after the first dose.</P>
<P>Three studies analyzed sleep bruxism indexes (<LINK REF="STD-Huynh--2006" TYPE="STUDY">Huynh 2006</LINK>; <LINK REF="STD-Lavigne-2001" TYPE="STUDY">Lavigne 2001</LINK>; <LINK REF="STD-Lobbezoo-1997a" TYPE="STUDY">Lobbezoo 1997a</LINK>), and three studies analyzed masseteric EMG activity (<LINK REF="STD-Etzel-1991" TYPE="STUDY">Etzel 1991</LINK>; <LINK REF="STD-Mohamed-1997" TYPE="STUDY">Mohamed 1997</LINK>; <LINK REF="STD-Raigrodski-2001a" TYPE="STUDY">Raigrodski 2001a</LINK>). Five studies analysed sleep variables (<LINK REF="STD-Huynh--2006" TYPE="STUDY">Huynh 2006</LINK>; <LINK REF="STD-Lavigne-2001" TYPE="STUDY">Lavigne 2001</LINK>; <LINK REF="STD-Lobbezoo-1997a" TYPE="STUDY">Lobbezoo 1997a</LINK>; <LINK REF="STD-Mohamed-1997" TYPE="STUDY">Mohamed 1997</LINK>; <LINK REF="STD-Raigrodski-2001a" TYPE="STUDY">Raigrodski 2001a</LINK>). Two studies analyzed pain intensity (<LINK REF="STD-Mohamed-1997" TYPE="STUDY">Mohamed 1997</LINK>; <LINK REF="STD-Raigrodski-2001b" TYPE="STUDY">Raigrodski 2001b</LINK>); and four studies included adverse events (<LINK REF="STD-Huynh--2006" TYPE="STUDY">Huynh 2006</LINK>; <LINK REF="STD-Lavigne-2001" TYPE="STUDY">Lavigne 2001</LINK>; <LINK REF="STD-Mohamed-1997" TYPE="STUDY">Mohamed 1997</LINK>; <LINK REF="STD-Raigrodski-2001a" TYPE="STUDY">Raigrodski 2001a</LINK>). One study analyzed level of anxiety and depression (<LINK REF="STD-Mohamed-1997" TYPE="STUDY">Mohamed 1997</LINK>), and one study analyzed perception of stress levels (<LINK REF="STD-Raigrodski-2001b" TYPE="STUDY">Raigrodski 2001b</LINK>).</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-10-02 21:50:22 +0100" MODIFIED_BY="Anne Lawson">
<P>We excluded eight studies for the following reasons: not an RCT (<LINK REF="STD-Chasins-1959" TYPE="STUDY">Chasins 1959</LINK>; <LINK REF="STD-Reim_x00e3_o-1982" TYPE="STUDY">Reimão 1982</LINK>; <LINK REF="STD-Saletu-2010" TYPE="STUDY">Saletu 2010</LINK>; <LINK REF="STD-Salute-2005" TYPE="STUDY">Salute 2005</LINK>; <LINK REF="STD-Tan-2000" TYPE="STUDY">Tan 2000</LINK>), clinical diagnosis not specified (<LINK REF="STD-Lee-2010" TYPE="STUDY">Lee 2010</LINK>), pilot study (<LINK REF="STD-Guarda_x002d_Nardini-2008" TYPE="STUDY">Guarda-Nardini 2008</LINK>), and large (66%) drop-out rate with only two participants (one in each group) completing the study (<LINK REF="STD-Lobbezoo-1997b" TYPE="STUDY">Lobbezoo 1997b</LINK>). We tried to contact the authors of two studies via email in order to clarify important issues; however, we did not obtain any answers (<LINK REF="STD-Guarda_x002d_Nardini-2008" TYPE="STUDY">Guarda-Nardini 2008</LINK>; <LINK REF="STD-Lee-2010" TYPE="STUDY">Lee 2010</LINK>).</P>
<P>Three studies are awaiting classification depending on the answer of the study authors regarding information necessary to the process of inclusion (<LINK REF="STD-Carra-2010" TYPE="STUDY">Carra 2010</LINK>; <LINK REF="STD-Ghanizadeh-2013" TYPE="STUDY">Ghanizadeh 2013</LINK>; <LINK REF="STD-Shim-2014" TYPE="STUDY">Shim 2014</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-10-02 21:50:22 +0100" MODIFIED_BY="Anne Lawson">
<P>We classified four of the seven studies (57%) as being at unclear risk of bias and three (42%) as being at low risk of bias. The most frequent risk of bias was allocation concealment, identified in approximately 60% of the studies, followed by lack of random sequence generation in about 30%. In both domains, we classified the studies as having unclear risk of bias because they lacked details.</P>
<P>We classified all studies as low risk of bias for blinding and incomplete outcome data. See 'Risk of bias' graph and 'Risk of bias' summary for more details (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
<ALLOCATION MODIFIED="2014-10-02 21:50:22 +0100" MODIFIED_BY="Anne Lawson">
<P>All studies were randomized, placebo-controlled, cross-over studies. Five studies used a computer-generated sequence (<LINK REF="STD-Huynh--2006" TYPE="STUDY">Huynh 2006</LINK>; <LINK REF="STD-Lavigne-2001" TYPE="STUDY">Lavigne 2001</LINK>; <LINK REF="STD-Lobbezoo-1997a" TYPE="STUDY">Lobbezoo 1997a</LINK>; <LINK REF="STD-Raigrodski-2001a" TYPE="STUDY">Raigrodski 2001a</LINK>; <LINK REF="STD-Raigrodski-2001b" TYPE="STUDY">Raigrodski 2001b</LINK>), and we classified them as being at low risk of selection bias. Two studies were unclear about the method used for sequence generation (<LINK REF="STD-Etzel-1991" TYPE="STUDY">Etzel 1991</LINK>; <LINK REF="STD-Mohamed-1997" TYPE="STUDY">Mohamed 1997</LINK>) (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
<P>Three studies used sealed opaque envelopes for allocation concealment and we classified them as having a low risk of selection bias (<LINK REF="STD-Huynh--2006" TYPE="STUDY">Huynh 2006</LINK>; <LINK REF="STD-Lavigne-2001" TYPE="STUDY">Lavigne 2001</LINK>; <LINK REF="STD-Lobbezoo-1997a" TYPE="STUDY">Lobbezoo 1997a</LINK>). Four studies were unclear about the method used for allocation concealment (<LINK REF="STD-Etzel-1991" TYPE="STUDY">Etzel 1991</LINK>; <LINK REF="STD-Mohamed-1997" TYPE="STUDY">Mohamed 1997</LINK>; <LINK REF="STD-Raigrodski-2001a" TYPE="STUDY">Raigrodski 2001a</LINK>; <LINK REF="STD-Raigrodski-2001b" TYPE="STUDY">Raigrodski 2001b</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2014-10-02 21:50:22 +0100" MODIFIED_BY="Anne Lawson">
<P>All studies described double-blind methods. Four studies described the characteristics of the placebo as being apparently identical to those of the active medication (<LINK REF="STD-Etzel-1991" TYPE="STUDY">Etzel 1991</LINK>; <LINK REF="STD-Lavigne-2001" TYPE="STUDY">Lavigne 2001</LINK>; <LINK REF="STD-Mohamed-1997" TYPE="STUDY">Mohamed 1997</LINK>; <LINK REF="STD-Raigrodski-2001a" TYPE="STUDY">Raigrodski 2001a</LINK>). We classified all studies as having low risk of bias for performance bias. We classified three studies as having low risk of bias for outcome assessment (detection bias) (<LINK REF="STD-Huynh--2006" TYPE="STUDY">Huynh 2006</LINK>; <LINK REF="STD-Lavigne-2001" TYPE="STUDY">Lavigne 2001</LINK>; <LINK REF="STD-Lobbezoo-1997a" TYPE="STUDY">Lobbezoo 1997a</LINK>), and four studies as unclear risk of detection bias (<LINK REF="STD-Etzel-1991" TYPE="STUDY">Etzel 1991</LINK>; <LINK REF="STD-Mohamed-1997" TYPE="STUDY">Mohamed 1997</LINK>; <LINK REF="STD-Raigrodski-2001a" TYPE="STUDY">Raigrodski 2001a</LINK>; <LINK REF="STD-Raigrodski-2001b" TYPE="STUDY">Raigrodski 2001b</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2014-10-02 21:50:22 +0100" MODIFIED_BY="Anne Lawson">
<P>There were no drop-outs in any of the studies. No authors report follow-up. We classified all studies as having low risk of attrition bias.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2014-10-02 21:50:22 +0100" MODIFIED_BY="Anne Lawson">
<P>Four studies were at high risk of reporting bias because they did not report sounds of tooth grinding or adverse effects (<LINK REF="STD-Etzel-1991" TYPE="STUDY">Etzel 1991</LINK>; <LINK REF="STD-Mohamed-1997" TYPE="STUDY">Mohamed 1997</LINK>; <LINK REF="STD-Raigrodski-2001a" TYPE="STUDY">Raigrodski 2001a</LINK>; <LINK REF="STD-Raigrodski-2001b" TYPE="STUDY">Raigrodski 2001b</LINK>). Two studies also did not report a washout period (<LINK REF="STD-Raigrodski-2001a" TYPE="STUDY">Raigrodski 2001a</LINK>; <LINK REF="STD-Raigrodski-2001b" TYPE="STUDY">Raigrodski 2001b</LINK>). Three studies were at low risk for selective reporting (<LINK REF="STD-Huynh--2006" TYPE="STUDY">Huynh 2006</LINK>; <LINK REF="STD-Lavigne-2001" TYPE="STUDY">Lavigne 2001</LINK>; <LINK REF="STD-Lobbezoo-1997a" TYPE="STUDY">Lobbezoo 1997a</LINK>). Although 
<LINK REF="STD-Lobbezoo-1997a" TYPE="STUDY">Lobbezoo 1997a</LINK> did not report a washout period, we categorized it as having a low risk of reporting bias because the authors stated that they did not observe any carry-over effects after the interventions.</P>
</SELECTIVE_REPORTING>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-10-02 21:50:22 +0100" MODIFIED_BY="Anne Lawson">
<P>One study used a cross-over design and included 25 participants divided into three arms: propranolol (10 participants), placebo (10 participants) or clonidine (16 participants) (<LINK REF="STD-Huynh--2006" TYPE="STUDY">Huynh 2006</LINK>). All other studies also used a cross-over design but compared only two arms.</P>
<SUBSECTION>
<HEADING LEVEL="3">Amitriptyline versus placebo</HEADING>
<P>Three studies compared amitriptyline with placebo with 10 participants each (<LINK REF="STD-Mohamed-1997" TYPE="STUDY">Mohamed 1997</LINK>; <LINK REF="STD-Raigrodski-2001a" TYPE="STUDY">Raigrodski 2001a</LINK>; <LINK REF="STD-Raigrodski-2001b" TYPE="STUDY">Raigrodski 2001b</LINK>).</P>
<P>There were no significant differences between amitriptyline and placebo groups for masseteric EMG activity per minute (SMD -0.28, 95% CI -0.91 to 0.34; P value = 0.37) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) (<LINK REF="STD-Mohamed-1997" TYPE="STUDY">Mohamed 1997</LINK>; <LINK REF="STD-Raigrodski-2001a" TYPE="STUDY">Raigrodski 2001a</LINK>).</P>
<P>Two studies compared amitriptyline with placebo and measured pain intensity using a VAS with a range of 0 to 10 with 0 representing no pain and 10 severe pain (<LINK REF="STD-Mohamed-1997" TYPE="STUDY">Mohamed 1997</LINK>; <LINK REF="STD-Raigrodski-2001b" TYPE="STUDY">Raigrodski 2001b</LINK>). Scores of 1 to 3 were ranked as mild, 4 to 6 as moderate and 7 to 9 as severe pain. Pain intensity was similar for amitriptyline and placebo (MD -0.64, 95% CI -1.72 to 0.45; P value = 0.25) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>) (<LINK REF="STD-Mohamed-1997" TYPE="STUDY">Mohamed 1997</LINK>; <LINK REF="STD-Raigrodski-2001b" TYPE="STUDY">Raigrodski 2001b</LINK>).</P>
<P>Similarly, there was no statistically significant difference in sleep duration between amitriptyline and placebo (MD 25.37, 95% CI -9.12 to 59.86; P value = 0.15) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>) (<LINK REF="STD-Mohamed-1997" TYPE="STUDY">Mohamed 1997</LINK>; <LINK REF="STD-Raigrodski-2001a" TYPE="STUDY">Raigrodski 2001a</LINK>).</P>
<P>There was no significant difference between amitriptyline and placebo in the perception of stress levels (MD -1.23, 95% CI -3.15 to 0.69; P value = 0.21) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>) (<LINK REF="STD-Raigrodski-2001b" TYPE="STUDY">Raigrodski 2001b</LINK>).</P>
<P>Adverse effects were reported in two studies (<LINK REF="STD-Mohamed-1997" TYPE="STUDY">Mohamed 1997</LINK>; <LINK REF="STD-Raigrodski-2001a" TYPE="STUDY">Raigrodski 2001a</LINK>). In <LINK REF="STD-Mohamed-1997" TYPE="STUDY">Mohamed 1997</LINK>, daytime sedation (drowsiness), difficulty in waking in the morning, insomnia and xerostomia were reported by five participants of the amitriptyline group and none in the placebo group. In <LINK REF="STD-Raigrodski-2001a" TYPE="STUDY">Raigrodski 2001a</LINK>, daytime sedation was reported by three participants, sleepiness by two, difficulty in awakening in the morning by two, increased appetite by two, irritability by one and increased clenching by one in the amitriptyline group; in the placebo group, only one participant reported neck stiffness and shoulder pains lasting for three days.</P>
<P>Data of the level of anxiety and depression outcomes were inappropriately reported (<LINK REF="STD-Mohamed-1997" TYPE="STUDY">Mohamed 1997</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Bromocriptine versus placebo</HEADING>
<P>Only one study with seven participants reported four bruxism variables and seven sleep variables for bromocriptine versus placebo (<LINK REF="STD-Lavigne-2001" TYPE="STUDY">Lavigne 2001</LINK>). There were no statistically significant differences between groups for bruxism variables (bruxism episodes per hour: MD 0.60, 95% CI -2.93 to 4.13; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>; bruxism bursts per hour: MD -2.00, 95% CI -53.47 to 49.47; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>; bruxism bursts per episode: MD 0.50, 95% CI -1.85 to 2.85; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>; number of episodes with grinding noise: MD 2.40, 95% CI -24.00 to 28.80; <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>).<BR/>No statistically significant differences between groups were found in the sleep variables (sleep duration (minutes): MD 5.80, 95% CI -47.01 to 58.61; <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>; sleep efficiency (%): MD 0, 95% CI -5.39 to 5.39; P value = 1.0; <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>; sleep stages 1 and 2 (%): MD 4.90, 95% CI -3.40 to 13.20; <LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>; sleep stages 3 and 4 (%): MD -2.50, 95% CI -9.30 to 4.30; P value = 0.47; <LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>; sleep stage REM (%): MD -2.30, 95% CI -5.94 to 1.34; <LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK>; micro-arousals index: MD 0.80, 95% CI -2.25 to 3.85; P value = 0.61; <LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK>; sleep onset latency (minutes): MD -4.50, 95% CI -12.52 to 3.52; <LINK REF="CMP-002.11" TYPE="ANALYSIS">Analysis 2.11</LINK>). Domperidone was administered to the participants along with bromocriptine to prevent adverse events in this trial.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Clonidine versus placebo</HEADING>
<P>One study with 25 participants compare clonidine with placebo (<LINK REF="STD-Huynh--2006" TYPE="STUDY">Huynh 2006</LINK>).</P>
<P>The number of bruxism episodes per hour did not differ significantly between the clonidine and placebo groups (MD -2.41, 95% CI -4.84 to 0.02) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
<P>There were no significant differences between the clonidine and placebo groups (sleep duration (minutes): MD 2.90, 95% CI -15.26 to 21.06; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>; sleep efficiency (%): MD 0.40, 95% CI -1.62 to 2.42; <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>; micro-arousal index (%): MD 0.70, 95% CI -1.38 to 2.78; <LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>; sleep stage 1 (%): MD -0.20, 95% CI -1.86 to 1.46; <LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>).</P>
<P>There was a significant difference in the percentage of stage 2 sleep, favouring participants who received clonidine (MD 20.40, 95% CI 16.36 to 24.44) (<LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>).</P>
<P>There were no significant differences between clonidine and placebo groups in stage 3 sleep (%) (MD -0.30, 95% CI -2.53 to 1.93) (<LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>) and stage 4 sleep (%) (MD 0.40, 95% CI -2.43 to 3.23) (<LINK REF="CMP-003.08" TYPE="ANALYSIS">Analysis 3.8</LINK>).</P>
<P>There was a statistically significant difference in the percentage of REM sleep, favouring participants who received placebo compared with clonidine (MD -20.10, 95% CI -21.87 to -18.33) (<LINK REF="CMP-003.09" TYPE="ANALYSIS">Analysis 3.9</LINK>).<BR/>
</P>
<P>Adverse effects, such as mouth dryness, were reported by 2/16 participants in the placebo group and 7/16 participants in the clonidine group. Symptomatic morning hypotension was reported by 3/16 participants in the clonidine group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Propranolol versus placebo</HEADING>
<P>There was only one study with 25 participants comparing propranolol with placebo (<LINK REF="STD-Huynh--2006" TYPE="STUDY">Huynh 2006</LINK>).</P>
<P>There were no statistically significant differences between the propranolol and placebo groups for the following outcomes: bruxism episodes per hour (MD 1.16, 95% CI -1.89 to 4.21) (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>); sleep duration (minutes) (MD -17.10, 95% CI -50.43 to 16.23) (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>); sleep efficiency (%) (MD -0.70; 95% CI -7.21 to 5.81) (<LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>); micro-arousal index (%) (MD 1.10, 95% CI -4.46 to 6.66) (<LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>); sleep stage 1 (%) (MD 0, 95% CI -2.78 to 2.78) (<LINK REF="CMP-004.05" TYPE="ANALYSIS">Analysis 4.5</LINK>); sleep stage 2 (%) (MD -1.80, 95% CI -7.83 to 4.23) (<LINK REF="CMP-004.06" TYPE="ANALYSIS">Analysis 4.6</LINK>); sleep stage 3 (%) (MD 1.50, 95% CI -0.99 to 3.99) (<LINK REF="CMP-004.07" TYPE="ANALYSIS">Analysis 4.7</LINK>); sleep stage 4 (%) (MD 0.80, 95% CI -3.27 to 4.87) (<LINK REF="CMP-004.08" TYPE="ANALYSIS">Analysis 4.8</LINK>) and sleep stage REM (%) (MD -0.50, 95% CI -6.02 to 5.02) (<LINK REF="CMP-004.09" TYPE="ANALYSIS">Analysis 4.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Tryptophan versus placebo</HEADING>
<P>There was one study with eight participants comparing tryptophan with placebo (<LINK REF="STD-Etzel-1991" TYPE="STUDY">Etzel 1991</LINK>). Masseteric EMG activity per second did not differ significantly between the groups (SMD 0.08, 95% CI -0.90 to 1.06) (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Levodopa (Prolopa®) versus placebo</HEADING>
<P>There was only one study with 10 participants comparing levodopa with placebo (<LINK REF="STD-Lobbezoo-1997a" TYPE="STUDY">Lobbezoo 1997a</LINK>). There were no statistically significant differences between levodopa and placebo for bruxism episodes per hour of sleep (MD -1.47, 95% CI -3.64 to 0.70) (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>); bruxism bursts per episode (MD 0.06, 95% CI -2.47 to 2.59) (<LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>) and for micro-arousal index (MD 0.30, 95% CI -2.91 to 2.31) (<LINK REF="CMP-006.03" TYPE="ANALYSIS">Analysis 6.3</LINK>). The study authors analyzed others sleep variables but they did not report them.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse effects</HEADING>
<P>Only four of the seven studies reported adverse effects, all of which were self reported by the participants (<LINK REF="STD-Huynh--2006" TYPE="STUDY">Huynh 2006</LINK>; <LINK REF="STD-Lavigne-2001" TYPE="STUDY">Lavigne 2001</LINK>; <LINK REF="STD-Lobbezoo-1997a" TYPE="STUDY">Lobbezoo 1997a</LINK>; <LINK REF="STD-Mohamed-1997" TYPE="STUDY">Mohamed 1997</LINK>).</P>
<P>
<LINK REF="STD-Huynh--2006" TYPE="STUDY">Huynh 2006</LINK> reported that 3/16 participants taking clonidine had prolonged morning hypotension. <LINK REF="STD-Huynh--2006" TYPE="STUDY">Huynh 2006</LINK> reported that 7/16 participants taking propranolol had moderate-to-severe xerostomia (dry mouth) in the morning compared with 2/16 participants in the placebo group.</P>
<P>
<LINK REF="STD-Lobbezoo-1997a" TYPE="STUDY">Lobbezoo 1997a</LINK> prescribed benserazide 25 mg to the participants taking levodopa to reduce adverse effects of levodopa, while <LINK REF="STD-Lavigne-2001" TYPE="STUDY">Lavigne 2001</LINK> prescribed domperidone 30 minutes before bromocriptine or placebo to reduce side effects. There were no reports of adverse effects in either study (<LINK REF="STD-Lavigne-2001" TYPE="STUDY">Lavigne 2001</LINK>; <LINK REF="STD-Lobbezoo-1997a" TYPE="STUDY">Lobbezoo 1997a</LINK>).</P>
<P>
<LINK REF="STD-Mohamed-1997" TYPE="STUDY">Mohamed 1997</LINK> reported that 5/10 participants taking amitriptyline had daytime sedation (drowsiness), difficult in awakening in the morning, insomnia or xerostomia.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-10-03 13:15:25 +0100" MODIFIED_BY="Anne Lawson">
<SUMMARY_OF_RESULTS MODIFIED="2014-10-02 21:50:22 +0100" MODIFIED_BY="Anne Lawson">
<P>The studies included in this review reported several types of outcomes using different measurement tools. The studies that analyzed sleep variables and the bruxism index used PSG as a tool both for diagnosing the disease and for assessing the efficacy of the treatment. The studies that measured masseteric activity through a portable EMG unit assessed sleep duration using a sleep diary (time when the participant went to bed and awoke in the morning). Studies evaluating pain intensity levels and perception of stress used a visual analogue scale (VAS). Finally, adverse events were based on participants' reports.</P>
<SUBSECTION>
<HEADING LEVEL="3">Sleep-related outcomes</HEADING>
<P>Most of the included studies reported sleep-related outcomes (<LINK REF="STD-Huynh--2006" TYPE="STUDY">Huynh 2006</LINK>; <LINK REF="STD-Lavigne-2001" TYPE="STUDY">Lavigne 2001</LINK>; <LINK REF="STD-Lobbezoo-1997a" TYPE="STUDY">Lobbezoo 1997a</LINK>; <LINK REF="STD-Mohamed-1997" TYPE="STUDY">Mohamed 1997</LINK>; <LINK REF="STD-Raigrodski-2001a" TYPE="STUDY">Raigrodski 2001a</LINK>). These studies compared several different medications (propranolol, clonidine, bromocriptine, levodopa and amitriptyline) versus placebo.<BR/>
<BR/>Two studies reported only one sleep outcome, namely sleep duration assessed through a sleep diary (<LINK REF="STD-Mohamed-1997" TYPE="STUDY">Mohamed 1997</LINK>; <LINK REF="STD-Raigrodski-2001a" TYPE="STUDY">Raigrodski 2001a</LINK>). It was possible to pool the results of these two studies in a meta-analysis because they used the same drug (amitriptyline) in the same dosage (25 mg), although the duration of treatment was different (one week in <LINK REF="STD-Mohamed-1997" TYPE="STUDY">Mohamed 1997</LINK> and four weeks in <LINK REF="STD-Raigrodski-2001a" TYPE="STUDY">Raigrodski 2001a</LINK>). Based on the results of these individual studies and in their meta-analysis, there were no significant differences in the duration of sleep of participants taking amitriptyline or a placebo.</P>
<P>Three studies measured several different sleep-related outcome variables using PSG (<LINK REF="STD-Huynh--2006" TYPE="STUDY">Huynh 2006</LINK>; <LINK REF="STD-Lavigne-2001" TYPE="STUDY">Lavigne 2001</LINK>; <LINK REF="STD-Lobbezoo-1997a" TYPE="STUDY">Lobbezoo 1997a</LINK>). <LINK REF="STD-Huynh--2006" TYPE="STUDY">Huynh 2006</LINK> compared propranolol with placebo and detected no significant differences in any of the sleep-related outcomes (sleep duration; sleep efficiency; micro-arousal index; percentages of sleep stages 1, 2, 3, 4, and REM). In contrast, clonidine was significantly better than placebo in increasing the percentage of time spent in sleep stage 2, while placebo proved to be more favourable in increasing the percentage of time spent in the REM sleep stage. These results indicate that clonidine significantly increases the duration of sleep stage 2 and significantly decreases sleep REM. There were no significant differences for any of the other sleep variables assessed (sleep duration, sleep efficiency, micro-arousal index, sleep stages 1, 3, 4). When the participants were questioned about the quality of their sleep in a questionnaire, there were no significant differences between the groups taking propranolol versus placebo, or among the participants taking clonidine versus placebo.</P>
<P>
<LINK REF="STD-Lavigne-2001" TYPE="STUDY">Lavigne 2001</LINK> compared bromocriptine with placebo and reported no statistically significant differences in any of the sleep outcome variables tested (sleep duration; sleep efficiency; micro-arousal index; sleep onset latency; percentage of sleep stages 1, 2, 3, 4 and REM).</P>
<P>
<LINK REF="STD-Lobbezoo-1997a" TYPE="STUDY">Lobbezoo 1997a</LINK> evaluated the effect of bromocriptine versus placebo on the micro-arousal index and found no statistically significant difference.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sleep bruxism-related outcomes</HEADING>
<P>The study by <LINK REF="STD-Huynh--2006" TYPE="STUDY">Huynh 2006</LINK> found no statistically significant difference for the sleep bruxism index when comparing propranolol with placebo and clonidine with placebo. Although the difference was not significant, the results of this study suggest that participants receiving clonidine tend to have a lower sleep bruxism index.</P>
<P>When the participants were questioned in the morning about their subjective recounting of sleep bruxism (teeth clenching and grinding awareness), pain, stress and fatigue, there were no significant differences among the groups taking propranolol, clonidine or placebo. The lack of sleep bruxism awareness can be justified by the fact that the people who have this condition are unconscious of their grinding during the night, since this complaint is generally made by the person who regularly shares the participant's room.</P>
<P>According to the results of <LINK REF="STD-Lavigne-2001" TYPE="STUDY">Lavigne 2001</LINK>, there were no statistically significant differences in the number of bruxism episodes per hour, bruxism bursts per hour, bruxism bursts per episode or the number of episodes with grinding noise in participants taking bromocriptine versus placebo.</P>
<P>
<LINK REF="STD-Lobbezoo-1997a" TYPE="STUDY">Lobbezoo 1997a</LINK> compared levodopa, commercially known as Prolopa® Roche (levodopa 100 mg and benserazide 25 mg) with a placebo and reported no statistically significant differences for sleep bruxism variables (bruxism episodes per hour of sleep and bruxism bursts per episode).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Masseteric electromyography activity</HEADING>
<P>Masseteric EMG activity was reported by three studies, all of which used portable EMG equipment (<LINK REF="STD-Etzel-1991" TYPE="STUDY">Etzel 1991</LINK>; <LINK REF="STD-Mohamed-1997" TYPE="STUDY">Mohamed 1997</LINK>; <LINK REF="STD-Raigrodski-2001a" TYPE="STUDY">Raigrodski 2001a</LINK>). Meta-analysis was only possible for two of these studies, which compared amitriptyline with placebo (<LINK REF="STD-Mohamed-1997" TYPE="STUDY">Mohamed 1997</LINK>; <LINK REF="STD-Raigrodski-2001a" TYPE="STUDY">Raigrodski 2001a</LINK>). The individual analysis of the studies, as well as the meta-analysis, found no statistically significant differences between the placebo and the medication groups. Likewise, in the study conducted by <LINK REF="STD-Etzel-1991" TYPE="STUDY">Etzel 1991</LINK>, there were no statistically significant differences in masseteric EMG between tryptophan and placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Pain intensity</HEADING>
<P>Two studies compared amitriptyline with placebo and measured pain intensity using a VAS with a range of 0 to 10 with 0 representing no pain and 10 severe pain (<LINK REF="STD-Mohamed-1997" TYPE="STUDY">Mohamed 1997</LINK>; <LINK REF="STD-Raigrodski-2001b" TYPE="STUDY">Raigrodski 2001b</LINK>). Scores of 1 to 3 were ranked as mild, 4 to 6 as moderate and 7 to 9 as severe pain. The study by <LINK REF="STD-Mohamed-1997" TYPE="STUDY">Mohamed 1997</LINK>, which lasted one week, did not report statistically significant differences between the groups. In an attempt to find differences, the authors of the study headed by <LINK REF="STD-Raigrodski-2001b" TYPE="STUDY">Raigrodski 2001b</LINK> increased the duration of drug administration to four weeks, but did not detect significant differences. Although the durations of treatment differed, we performed a meta-analysis because the drug dosage was the same.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Perception of stress levels</HEADING>
<P>Only one study perception of stress levels in participants taking amitriptyline or placebo (<LINK REF="STD-Raigrodski-2001b" TYPE="STUDY">Raigrodski 2001b</LINK>). Perception of stress levels was evaluated using a VAS, whereby the absence of stress was score 0 and the most severe stress 10. Scores of 1 to 3.5 were ranked as mild, 3.5 to 7.5 as moderate and 7.5 to 10 as severe stress. There were no statistically significant differences between the groups.</P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2014-10-03 13:15:25 +0100" MODIFIED_BY="Anne Lawson">
<P>Only seven RCTs satisfied the selection criteria and were included in this review. This small number of studies was probably due to the inherent difficulties of conducting RCTs in assessing the effectiveness of medical treatments for sleep bruxism. For instance, it would be recommended that these types of studies assess several additional clinically relevant outcomes such as quality of life and sleep quality, among others, which require the use of appropriate questionnaires and polysomnography equipments.</P>
<P>The number of participants in each of the seven studies included in this review was small, ranging from seven to 16 participants per study. The small sample size of studies can overestimate the effects of interventions and this could be an additional potential bias. The studies categorized as being at low risk of bias were also those that used PSG, which is considered the gold standard for the diagnosis of bruxism, and, therefore, they were considered efficacy studies.</P>
<P>The analysis of the results of the clinical trials included in the review identified statistically significant differences in only two outcomes between the groups treated with clonidine versus placebo. The lack of other significant differences may be due to the small number of participants included in the studies analysed, which tends to favour the null hypothesis because there is insufficient statistical power to detect small differences between the groups. Due to the large number of drugs and outcomes in these seven studies, it was possible to perform meta-analyses for the outcomes of sleep duration, masseteric EMG activity per minute and pain intensity in studies that compared amitriptyline with placebo.</P>
<P>There is a lack of evidence on both the effectiveness and the safety of using medications for the treatment of sleep bruxism.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2014-10-02 21:50:22 +0100" MODIFIED_BY="Anne Lawson">
<P>Overall, the methodological quality of the seven trials was unclear. Only three of the seven studies provided a detailed description of allocation concealment and of how the allocation sequence was generated. In several studies, the inclusion criteria were not specified and outcomes could not be analysed because they were inappropriately described. We contacted authors to try to clarify these issues, but even after these contacts, we classified only three studies as having a low risk of bias for allocation concealment, while we classified four studies as having an unclear risk. Few authors responded to the requests that were made.</P>
<P>All studies had a cross-over design. In contrast to parallel studies, each individual in a cross-over study receives two or more interventions in random order, and each participant acts as their own control. In this type of study, the washout period is very important because the treatment may affect the condition in question in the subsequent phases, in which the participant systematically differs from the initial state (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). Unfortunately, some studies did not describe the washout period and this could bias the review because we cannot infer whether there was a carry-over effect. It was not possible to conduct the tests for funnel plot asymmetry because only two studies were included in the meta-analysis.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-10-02 13:52:30 +0100" MODIFIED_BY="[Empty name]">
<P>Full data were not available from all studies, despite our attempts to obtain these by contacting study authors. We did not identify any other likely sources of biases in the review process. </P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-10-02 21:50:22 +0100" MODIFIED_BY="Anne Lawson">
<P>The findings of our review coincide with other studies that also conclude that more studies are needed to assess the effectiveness and safety of pharmacological treatments for sleep bruxism (<LINK REF="REF-Carra-2012" TYPE="REFERENCE">Carra 2012</LINK>; <LINK REF="REF-de-la-Hoz_x002d_Aizpurua-2011" TYPE="REFERENCE">de la Hoz-Aizpurua 2011</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-10-02 21:50:23 +0100" MODIFIED_BY="Anne Lawson">
<IMPLICATIONS_PRACTICE MODIFIED="2014-10-02 21:50:22 +0100" MODIFIED_BY="Anne Lawson">
<P>There was insufficient evidence to assess the effectiveness of pharmacotherapy for treating sleep bruxism.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-10-02 21:50:23 +0100" MODIFIED_BY="Anne Lawson">
<P>This review suggests that there is a need for more well-designed randomized controlled clinical trials with a larger number of participants to clarify whether there is any benefit from pharmacotherapy in the treatment of sleep bruxism.</P>
<P>The method used for randomization (use of random number tables, randomization generator or others), and for allocation concealment (opaque sealed envelopes or other) should be appropriate and well described by the author. Ideally, the study design should be parallel in order to eliminate potential biases of cross-over studies. Blinding of outcome assessors, of data analysts and, when possible, of the participants, should be used and described. The diagnostic criteria for sleep bruxism should be standardized in accordance with the recommendations of the American Sleep Disorders Association, as well as the name used for the disease, in order to avoid misunderstandings regarding types of bruxism. For example, the term "nocturnal bruxism" is often used instead of "sleep bruxism" but, obviously, people can sleep and grind their teeth both during the day and during the night. Outcomes such as tooth wear in adults, morning headache, morning fatigue, neck and shoulder pain, quality of life, tolerability of devices, costs and patient satisfaction must be evaluated. The results should be expressed as risk ratios with 95% confidence intervals, or by means. In case of drop-outs, the analysis should be by intention to treat, and all the data must be described by the study author. Adverse effects should be reported and finally, the length of follow-up should be longer.</P>
<P>The primary outcome of most studies was bruxism index measured through polysomnography or electromyography. It is questionable if this outcome is relevant for the participants and their families. Outcomes that are more clinically relevant for the participants, such as quality of life or sleep quality, should be included in future studies.</P>
<P>In summary, because of the limitations in the methods used in the included studies it is recommended that the future studies should be randomized controlled studies with rigorous methodology and have adequate sample sizes with sufficient power to detect differences in the main outcome that should be clinically relevant. It is also suggested that the guidelines produced by the Consolidated Standards of Reporting Trials (CONSORT) group be utilized, since their use improves the quality of trials (<LINK REF="REF-CONSORT-2010" TYPE="REFERENCE">CONSORT 2010</LINK>).<BR/>
</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-10-02 21:50:23 +0100" MODIFIED_BY="Anne Lawson">
<P>The review authors wish to thanks the Cochrane Movement Disorders Group and the Brazilian Cochrane Centre.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-10-02 21:50:23 +0100" MODIFIED_BY="Anne Lawson">
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-10-03 13:29:25 +0100" MODIFIED_BY="Anne Lawson">
<P>Cristiane Rufino Macedo (CRM): main author of protocol, protocol development, study selection, quality assessment, data extraction and data entry, interpretation of results, writing up of review.</P>
<P>Elizeu Coutinho Macedo (ECM): quality assessment, third party in the event of disagreement among authors.</P>
<P>Maria Regina Torloni (MRT): study selection, quality assessment, data extraction, writing up of review.</P>
<P>Ademir Silva (ABS): assistance with protocol and review, interpretation of results, third party in the event of disagreement among authors, expertise in the field.</P>
<P>Gilmar Prado (GFP): co-ordinator, interpretation of results, expertise in the field.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-10-02 21:50:23 +0100" MODIFIED_BY="Anne Lawson">
<P>The following data analysis was in the original protocol and has since been removed: fixed-effect model (replaced by random-effects model). An additional exclusion criterion was added after the publication of the protocol: "medications known to be associated with sleep bruxism, such as antipsychotic drugs or amphetamines, among others" (<LINK TAG="METHODS" TYPE="SECTION">Methods</LINK>).</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-10-02 22:13:51 +0100" MODIFIED_BY="Anne Lawson">
<STUDIES MODIFIED="2014-10-02 22:13:51 +0100" MODIFIED_BY="Anne Lawson">
<INCLUDED_STUDIES MODIFIED="2014-10-02 22:11:17 +0100" MODIFIED_BY="Anne Lawson">
<STUDY DATA_SOURCE="PUB" ID="STD-Etzel-1991" MODIFIED="2014-10-02 22:09:50 +0100" MODIFIED_BY="Anne Lawson" NAME="Etzel 1991" YEAR="1991">
<REFERENCE MODIFIED="2014-10-02 22:09:50 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Etzel KR, Stockstill JW, Rugh JD, Fisher JG</AU>
<TI>Tryptophan supplementation for nocturnal bruxism: report of negative results</TI>
<SO>Journal of Craniomandibular Disorders: Facial &amp; Oral Pain</SO>
<YR>1991</YR>
<VL>5</VL>
<NO>2</NO>
<PG>115-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huynh--2006" MODIFIED="2014-10-02 22:10:13 +0100" MODIFIED_BY="Anne Lawson" NAME="Huynh  2006" YEAR="2006">
<REFERENCE MODIFIED="2014-10-02 22:09:59 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huynh N, Guitard F, Manzine C, Montplaisir JY, de Champlain J, Lavigne GJ</AU>
<TI>Lack of effect of propranolol on sleep bruxism: a controlled double-blind study</TI>
<SO>Sleep</SO>
<YR>2004</YR>
<VL>27</VL>
<NO>Abstr Suppl</NO>
<PG>A 281</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-10-02 22:10:13 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Huynh N, Lavigne GJ, Lanfranchi PA, Montplaisir JY, de Champlain J</AU>
<TI>The effect of 2 sympatholytic medications - propranolol and clonidine-on sleep bruxism: experimental randomized controlled studies</TI>
<SO>Sleep</SO>
<YR>2006</YR>
<VL>29</VL>
<NO>3</NO>
<PG>307-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lavigne-2001" MODIFIED="2014-10-02 22:10:23 +0100" MODIFIED_BY="Anne Lawson" NAME="Lavigne 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-10-02 22:10:23 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lavigne GJ, Soucy JP, Lobbezoo F, Manzini C, Blanchet PJ, Montplaisir JY</AU>
<TI>Double-blind, crossover, placebo-controlled trial of bromocriptine in patients with sleep bruxism</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>2001</YR>
<VL>24</VL>
<NO>3</NO>
<PG>145-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lobbezoo-1997a" MODIFIED="2014-10-02 22:10:47 +0100" MODIFIED_BY="Anne Lawson" NAME="Lobbezoo 1997a" YEAR="1997">
<REFERENCE MODIFIED="2014-10-02 22:10:35 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lobbezoo F, Lavigne GJ, Tanguay R, Montplaisir JY</AU>
<TI>Does L-dopa exacerbate sleep bruxism?</TI>
<SO>Journal of Oral Rehabilitation</SO>
<YR>1996</YR>
<VL>23</VL>
<NO>8</NO>
<PG>556-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-10-02 22:10:47 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lobbezoo F, Lavigne GJ, Tanguay R, Montplaisir JY</AU>
<TI>The effect of catecholamine precursor L-dopa on sleep bruxism: a controlled clinical trial</TI>
<SO>Movement Disorders</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>1</NO>
<PG>73-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mohamed-1997" MODIFIED="2014-10-02 22:10:58 +0100" MODIFIED_BY="Anne Lawson" NAME="Mohamed 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-10-02 22:10:58 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mohamed SE, Christensen LV, Penchas J</AU>
<TI>A randomized double-blind clinical trial of the effect of amitriptyline on nocturnal masseteric motor activity (sleep bruxism)</TI>
<SO>Journal of Craniomandibular Practice</SO>
<YR>1997</YR>
<VL>15</VL>
<NO>4</NO>
<PG>326-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raigrodski-2001a" MODIFIED="2014-10-02 22:11:09 +0100" MODIFIED_BY="Anne Lawson" NAME="Raigrodski 2001a" YEAR="2001">
<REFERENCE MODIFIED="2014-10-02 22:11:09 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raigrodski AJ, Christensen LV, Mohamed SE, Gardiner DM</AU>
<TI>The effect of four-week administration of amitriptyline on sleep bruxism. A double-blind crossover clinical study</TI>
<SO>Journal of Craniomandibular Practice</SO>
<YR>2001</YR>
<VL>19</VL>
<NO>1</NO>
<PG>21-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raigrodski-2001b" MODIFIED="2014-10-02 22:11:17 +0100" MODIFIED_BY="Anne Lawson" NAME="Raigrodski 2001b" YEAR="2001">
<REFERENCE MODIFIED="2014-10-02 22:11:17 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raigrodski AJ, Mohamed SE, Gardiner DM</AU>
<TI>The effect of amitriptyline on pain intensity and perception of stress in bruxers</TI>
<SO>Journal of Prosthodontics</SO>
<YR>2001</YR>
<VL>10</VL>
<NO>2</NO>
<PG>73-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-10-02 22:13:16 +0100" MODIFIED_BY="Anne Lawson">
<STUDY DATA_SOURCE="PUB" ID="STD-Chasins-1959" MODIFIED="2014-10-02 22:11:43 +0100" MODIFIED_BY="Anne Lawson" NAME="Chasins 1959" YEAR="1959">
<REFERENCE MODIFIED="2014-10-02 22:11:43 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chasins AI</AU>
<TI>Methocarbamal (robaxin) as an adjunct in the treatment of bruxism</TI>
<SO>Journal of Dental Medicine</SO>
<YR>1959</YR>
<VL>14</VL>
<NO>3</NO>
<PG>166-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guarda_x002d_Nardini-2008" MODIFIED="2014-10-02 22:12:16 +0100" MODIFIED_BY="Anne Lawson" NAME="Guarda-Nardini 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-10-02 22:12:16 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guarda-Nardini L, Manfredini D, Salamone M, Salmaso L, Tonello S, Ferronato G</AU>
<TI>Efficacy of botulinum toxin in treating myofascial pain in bruxers: a controlled placebo pilot study</TI>
<SO>Cranio</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>2</NO>
<PG>126-35</PG>
<IDENTIFIERS MODIFIED="2013-05-29 22:12:51 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="18468272"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2010" MODIFIED="2014-10-02 22:12:26 +0100" MODIFIED_BY="Anne Lawson" NAME="Lee 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-10-02 22:12:26 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee SJ, McCall WD Jr, Kim YK, Chung SC, Chung JW</AU>
<TI>Effect of botulinum toxin injection on nocturnal bruxism: a randomized controlled trial</TI>
<SO>American Journal of Physical Medicine &amp; Rehabilitation</SO>
<YR>2010</YR>
<VL>89</VL>
<NO>1</NO>
<PG>16-23</PG>
<IDENTIFIERS MODIFIED="2013-05-29 22:30:54 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="19855255"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lobbezoo-1997b" MODIFIED="2014-10-02 22:12:49 +0100" MODIFIED_BY="Anne Lawson" NAME="Lobbezoo 1997b" YEAR="1997">
<REFERENCE MODIFIED="2014-10-02 22:12:40 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lobbezoo F, Soucy JP, Hartman NG, Montplaisir JY, Lavigne GJ</AU>
<TI>Effects of the D2 receptor agonist bromocriptine on sleep bruxism: report of two single-patient clinical trials</TI>
<SO>Journal of Dental Research</SO>
<YR>1997</YR>
<VL>79</VL>
<NO>9</NO>
<PG>1610-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-10-02 22:12:49 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lobbezoo F, Soucy JP, Hartman NG, Montplaisir JY, Lavigne GJ</AU>
<TI>Polysomnographic and scintigraphic demonstration of the effects of the dopamine D2 receptor agonist bromocriptine on sleep bruxism</TI>
<SO>Journal of Oral Rehabilitation</SO>
<YR>1998</YR>
<VL>25</VL>
<NO>3</NO>
<PG>228</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reim_x00e3_o-1982" MODIFIED="2014-10-02 22:12:58 +0100" MODIFIED_BY="Anne Lawson" NAME="Reimão 1982" YEAR="1982">
<REFERENCE MODIFIED="2014-10-02 22:12:58 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reimão R, Lefévre AB</AU>
<TI>Evaluation of flurazepam and placebo on sleep disorders in childhood</TI>
<SO>Arquivos de Neuro-psiquiatria</SO>
<YR>1982</YR>
<VL>40</VL>
<NO>1</NO>
<PG>1-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saletu-2010" MODIFIED="2014-10-02 22:13:07 +0100" MODIFIED_BY="Anne Lawson" NAME="Saletu 2010" YEAR="2009">
<REFERENCE MODIFIED="2014-10-02 22:13:07 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saletu A, Parapatics S, Anderer P, Matejka M, Saletu B</AU>
<TI>Controlled clinical, polysomnographic and psychometric studies on differences between sleep bruxers and controls and acute effects of clonazepam as compared with placebo</TI>
<SO>European Archives of Psychiatry and Clinical Neuroscience</SO>
<YR>2010</YR>
<VL>260</VL>
<NO>2</NO>
<PG>163-74</PG>
<IDENTIFIERS MODIFIED="2013-05-29 22:03:09 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="19603241"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salute-2005" MODIFIED="2014-10-02 22:13:16 +0100" MODIFIED_BY="Anne Lawson" NAME="Salute 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-10-02 22:13:16 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saletu A, Parapatics S, Saletu B, Anderer P, Prause W, Putz H, et al</AU>
<TI>On the pharmacotherapy of sleep bruxism: placebo-controlled polysomnographic and psychometric studies with clonazepam</TI>
<SO>Neuropsychobiology</SO>
<YR>2005</YR>
<VL>51</VL>
<NO>4</NO>
<PG>214-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tan-2000" MODIFIED="2014-09-29 19:09:32 +0100" MODIFIED_BY="Anne Lawson" NAME="Tan 2000" YEAR="2000">
<REFERENCE MODIFIED="2014-09-29 19:09:32 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tan EK, Jankovic J</AU>
<TI>Treating severe bruxism with botulinum toxin</TI>
<SO>Journal of American Dental Association</SO>
<YR>2000</YR>
<VL>131</VL>
<NO>2</NO>
<PG>211-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2014-10-02 22:13:51 +0100" MODIFIED_BY="Anne Lawson">
<STUDY DATA_SOURCE="PUB" ID="STD-Carra-2010" MODIFIED="2013-05-28 18:06:32 +0100" MODIFIED_BY="[Empty name]" NAME="Carra 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-05-28 18:06:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carra MC, Macaluso GM, Rompre PH, Huynh N, Parrino L, Terzano MG, et al</AU>
<TI>Clonidine has a paradoxical effect on cyclic arousal and sleep bruxism during NREM sleep</TI>
<SO>Sleep</SO>
<YR>2010</YR>
<VL>33</VL>
<NO>12</NO>
<PG>1711-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="21120152"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ghanizadeh-2013" MODIFIED="2014-10-02 22:13:42 +0100" MODIFIED_BY="Anne Lawson" NAME="Ghanizadeh 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-10-02 22:13:42 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ghanizadeh A, Zare S</AU>
<TI>A preliminary randomised double-blind placebo-controlled clinical trial of hydroxyzine for treating sleep bruxism in children</TI>
<SO>Journal of Oral Rehabilitation</SO>
<YR>2013</YR>
<VL>40</VL>
<NO>6</NO>
<PG>413-7</PG>
<IDENTIFIERS MODIFIED="2014-08-18 21:48:32 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="23550945"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shim-2014" MODIFIED="2014-10-02 22:13:51 +0100" MODIFIED_BY="Anne Lawson" NAME="Shim 2014" YEAR="2014">
<REFERENCE MODIFIED="2014-10-02 22:13:51 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shim YJ, Lee MK, Kato T, Park HU, Heo K, Kim ST</AU>
<TI>Effects of botulinum toxin on jaw motor events during sleep in sleep bruxism patients: a polysomnographic evaluation</TI>
<SO>Journal of Clinical Sleep Medicine</SO>
<YR>2014</YR>
<VL>10</VL>
<NO>3</NO>
<PG>291-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-10-02 22:04:45 +0100" MODIFIED_BY="Anne Lawson">
<ADDITIONAL_REFERENCES MODIFIED="2014-10-02 22:04:45 +0100" MODIFIED_BY="Anne Lawson">
<REFERENCE ID="REF-AASD-2005" MODIFIED="2014-10-02 21:58:08 +0100" MODIFIED_BY="Anne Lawson" NAME="AASD 2005" TYPE="BOOK_SECTION">
<AU>American Academy of Sleep Medicine</AU>
<TI>Sleep related bruxism</TI>
<SO>International Classification of Sleep Disorders: Diagnostic and Coding Manual</SO>
<YR>2005</YR>
<PG>189-92</PG>
<EN>2nd</EN>
<PB>The Academy</PB>
<CY>Westchester, IL</CY>
<IDENTIFIERS MODIFIED="2014-09-29 19:10:36 +0100" MODIFIED_BY="Anne Lawson"/>
</REFERENCE>
<REFERENCE ID="REF-Abe-1966" MODIFIED="2014-10-02 21:58:25 +0100" MODIFIED_BY="Anne Lawson" NAME="Abe 1966" TYPE="JOURNAL_ARTICLE">
<AU>Abe K, Shimakawa M</AU>
<TI>Genetic and developmental aspects of sleeptalking and teeth-grinding</TI>
<SO>Acta Paedopsychiatrica</SO>
<YR>1966</YR>
<VL>33</VL>
<NO>11</NO>
<PG>339-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barder-2000" MODIFIED="2014-10-02 21:58:39 +0100" MODIFIED_BY="Anne Lawson" NAME="Barder 2000" TYPE="JOURNAL_ARTICLE">
<AU>Barder G, Lavigne G</AU>
<TI>Sleep bruxism: an overview of an oromandibular sleep movement disorder</TI>
<SO>Sleep Medicine Reviews</SO>
<YR>2000</YR>
<VL>4</VL>
<NO>1</NO>
<PG>27-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carlsson-2003" MODIFIED="2014-10-02 21:58:50 +0100" MODIFIED_BY="Anne Lawson" NAME="Carlsson 2003" TYPE="JOURNAL_ARTICLE">
<AU>Carlsson GE, Egermark I, Magnusson T</AU>
<TI>Predictors of bruxism, other oral parafunctions, and tooth wear over a 20-year follow-up period</TI>
<SO>Journal of Orofacial Pain</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>1</NO>
<PG>50-7</PG>
<IDENTIFIERS MODIFIED="2013-05-21 20:56:30 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="12756931"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Carra-2012" MODIFIED="2014-10-02 21:58:58 +0100" MODIFIED_BY="Anne Lawson" NAME="Carra 2012" TYPE="JOURNAL_ARTICLE">
<AU>Carra MC, Huynh N, Lavigne G</AU>
<TI>Sleep bruxism: a comprehensive overview for the dental clinician interested in sleep medicine</TI>
<SO>Dental Clinics of North America</SO>
<YR>2012</YR>
<VL>56</VL>
<NO>2</NO>
<PG>387-413</PG>
<IDENTIFIERS MODIFIED="2013-05-21 20:57:00 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="22480810"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-CONSORT-2010" MODIFIED="2014-10-02 21:59:08 +0100" MODIFIED_BY="Anne Lawson" NAME="CONSORT 2010" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Altman DG, Moher D</AU>
<TI>CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2010</YR>
<VL>340</VL>
<PG>c332</PG>
<IDENTIFIERS MODIFIED="2013-05-28 18:42:45 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="20332509"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-de-la-Hoz_x002d_Aizpurua-2011" MODIFIED="2014-10-02 21:59:21 +0100" MODIFIED_BY="Anne Lawson" NAME="de la Hoz-Aizpurua 2011" TYPE="JOURNAL_ARTICLE">
<AU>de la Hoz-Aizpurua JL, Diaz-Alonso E, LaTouche-Arbizu R, Mesa-Jimenez J</AU>
<TI>Sleep bruxism. Conceptual review and update</TI>
<SO>Medicina Oral, Patologia Oral y Cirugia Bucal</SO>
<YR>2011</YR>
<VL>16</VL>
<NO>2</NO>
<PG>e231-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="21196839"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dorland-1994" MODIFIED="2014-10-02 21:59:34 +0100" MODIFIED_BY="Anne Lawson" NAME="Dorland 1994" TYPE="BOOK">
<AU>Dorland</AU>
<SO>Dorland's Medical Illustrated Dictionary</SO>
<YR>1994</YR>
<EN>28th</EN>
<PB>Saunders</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Faulkner-1990" NAME="Faulkner 1990" TYPE="JOURNAL_ARTICLE">
<AU>Faulkner KBD</AU>
<TI>Bruxism: a review of the literature. Part 1</TI>
<SO>Australian Dental Journal</SO>
<YR>1990</YR>
<VL>35</VL>
<NO>3</NO>
<PG>266-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ferini_x002d_Strambi-2011" MODIFIED="2014-10-02 22:02:10 +0100" MODIFIED_BY="Anne Lawson" NAME="Ferini-Strambi 2011" TYPE="JOURNAL_ARTICLE">
<AU>Ferini-Strambi L, Pozzi P, Manconi M, Zucconi M, Oldani A</AU>
<TI>Bruxism and nocturnal groaning</TI>
<SO>Archives Italiennes de Biologie</SO>
<YR>2011</YR>
<VL>149</VL>
<NO>4</NO>
<PG>467-77</PG>
<IDENTIFIERS MODIFIED="2013-05-21 21:18:53 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="22205592"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Glacos-1981" NAME="Glacos 1981" TYPE="JOURNAL_ARTICLE">
<AU>Glacos AG</AU>
<TI>Incidence of diurnal and nocturnal bruxism</TI>
<SO>Journal of Prosthetic Dentistry</SO>
<YR>1981</YR>
<VL>45</VL>
<NO>5</NO>
<PG>545-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011a" MODIFIED="2014-10-02 22:02:24 +0100" MODIFIED_BY="Anne Lawson" NAME="Higgins 2011a" TYPE="OTHER">
<AU>Higgins JPT and Deeks JJ</AU>
<TI>Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011b" MODIFIED="2014-10-02 22:02:34 +0100" MODIFIED_BY="Anne Lawson" NAME="Higgins 2011b" TYPE="OTHER">
<AU>Higgins JPT, Altman DG, Sterne JAC</AU>
<TI>Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kato-2001" MODIFIED="2014-10-02 22:02:43 +0100" MODIFIED_BY="Anne Lawson" NAME="Kato 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kato T, Thie NM, Montplaisir JY, Lavigne GJ</AU>
<TI>Bruxism and orofacial movements during sleep</TI>
<SO>Dental Clinics of North America</SO>
<YR>2001</YR>
<VL>45</VL>
<NO>4</NO>
<PG>657-84</PG>
<IDENTIFIERS MODIFIED="2013-05-21 21:07:48 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="11699235"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kato-2003" NAME="Kato 2003" TYPE="JOURNAL_ARTICLE">
<AU>Kato T, Monpalisir JY, Guitard F, Sessle BJ, Lund JP, Lavigne GJ</AU>
<TI>Evidence that experimentally induced sleep bruxism is a consequence of transient arousal</TI>
<SO>Journal of Dental Research</SO>
<YR>2003</YR>
<VL>82</VL>
<NO>4</NO>
<PG>284-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lavigne-1994" NAME="Lavigne 1994" TYPE="JOURNAL_ARTICLE">
<AU>Lavigne GJ, Montplaisir JY</AU>
<TI>Restless legs syndrome and sleep bruxism: prevalence and association among Canadians</TI>
<SO>Sleep</SO>
<YR>1994</YR>
<VL>17</VL>
<NO>8</NO>
<PG>739-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lavigne-1996" MODIFIED="2014-10-02 22:03:10 +0100" MODIFIED_BY="Anne Lawson" NAME="Lavigne 1996" TYPE="JOURNAL_ARTICLE">
<AU>Lavigne GJ, Rompre PH, Montplaisir JY</AU>
<TI>Sleep bruxism: validity of clinical research diagnostic criteria in a controlled polysomnographic study</TI>
<SO>Journal of Dental Research</SO>
<YR>1996</YR>
<VL>75</VL>
<NO>1</NO>
<PG>546-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lavigne-1997" MODIFIED="2009-01-19 13:37:51 +0000" MODIFIED_BY="[Empty name]" NAME="Lavigne 1997" TYPE="JOURNAL_ARTICLE">
<AU>Lavigne GJ, Lobbezoo F, Rompre PH, Nielsen TA, Montplaisir JY</AU>
<TI>Cigarette smoking as a risk factor or an exacerbating factor for restless legs syndrome and sleep bruxism</TI>
<SO>Sleep</SO>
<YR>1997</YR>
<VL>20</VL>
<NO>4</NO>
<PG>290-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lavigne-2005" MODIFIED="2014-10-02 22:03:22 +0100" MODIFIED_BY="Anne Lawson" NAME="Lavigne 2005" TYPE="BOOK_SECTION">
<AU>Lavigne GJ, Manzine C, Kato T</AU>
<TI>Sleep bruxism</TI>
<SO>Principles and Practice of Sleep Medicine</SO>
<YR>2005</YR>
<PG>946-59</PG>
<EN>4th</EN>
<ED>Kryger MH, Roth T, Dement WC</ED>
<PB>Saunders</PB>
<CY>Philadelphia, PA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lavigne-2007" MODIFIED="2014-10-02 22:03:32 +0100" MODIFIED_BY="Anne Lawson" NAME="Lavigne 2007" TYPE="JOURNAL_ARTICLE">
<AU>Lavigne GJ, Huynh N, Kato T, Okura K, Adachi K, Yao D, et al</AU>
<TI>Genesis of sleep bruxism: motor and autonomic-cardiac interactions</TI>
<SO>Archives of Oral Biology</SO>
<YR>2007</YR>
<VL>52</VL>
<NO>4</NO>
<PG>381-4</PG>
<IDENTIFIERS MODIFIED="2013-05-21 21:20:40 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="17313939"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lavigne-2008" MODIFIED="2014-10-02 22:03:43 +0100" MODIFIED_BY="Anne Lawson" NAME="Lavigne 2008" TYPE="JOURNAL_ARTICLE">
<AU>Lavigne GJ, Khoury S, Abe S, Yamaguchi T, Raphael K</AU>
<TI>Bruxism physiology and pathology: an overview for clinicians</TI>
<SO>Journal of Oral Rehabilitation</SO>
<YR>2008</YR>
<VL>35</VL>
<NO>7</NO>
<PG>476-94</PG>
<IDENTIFIERS MODIFIED="2013-05-21 20:51:16 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="18557915"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2011" MODIFIED="2014-10-02 22:04:04 +0100" MODIFIED_BY="Anne Lawson" NAME="Lefebvre 2011" TYPE="OTHER">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lobbezoo-1996" MODIFIED="2014-10-02 22:04:14 +0100" MODIFIED_BY="Anne Lawson" NAME="Lobbezoo 1996" TYPE="JOURNAL_ARTICLE">
<AU>Lobbezoo F, Soucy JP, Montplasir JY, Lavigne GJ</AU>
<TI>Striatal D2 receptor blinding in sleep bruxism: a controlled study with iodine-123-iodobenzamide and single photon emission computed tomography</TI>
<SO>Journal of Dental Research</SO>
<YR>1996</YR>
<VL>75</VL>
<NO>10</NO>
<PG>1804-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lobbezoo-2001" NAME="Lobbezoo 2001" TYPE="JOURNAL_ARTICLE">
<AU>Lobbezoo F, Naeije M</AU>
<TI>Bruxism is mainly regulated centrally, not peripherally</TI>
<SO>Journal of Oral Rehabilitation</SO>
<YR>2001</YR>
<VL>28</VL>
<NO>12</NO>
<PG>1085-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Magee-1970" MODIFIED="2014-10-02 22:04:23 +0100" MODIFIED_BY="Anne Lawson" NAME="Magee 1970" TYPE="JOURNAL_ARTICLE">
<AU>Magee KR</AU>
<TI>Bruxism related to levodopa therapy</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1970</YR>
<VL>214</VL>
<NO>1</NO>
<PG>147</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Melis-2003" NAME="Melis 2003" TYPE="JOURNAL_ARTICLE">
<AU>Melis M, Abou Atme YS</AU>
<TI>Prevalence of bruxism awareness in a Sardinian population</TI>
<SO>Cranio</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>2</NO>
<PG>144-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ohayon-2001" NAME="Ohayon 2001" TYPE="JOURNAL_ARTICLE">
<AU>Ohayon MM, Li KK, Guilleminault C</AU>
<TI>Risk factors for sleep bruxism in the general population</TI>
<SO>Chest</SO>
<YR>2001</YR>
<VL>119</VL>
<NO>1</NO>
<PG>53-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Partinen-1994" MODIFIED="2014-10-02 22:04:34 +0100" MODIFIED_BY="Anne Lawson" NAME="Partinen 1994" TYPE="BOOK_SECTION">
<AU>Partinen M</AU>
<TI>Epidemiology sleep disorder</TI>
<SO>Principles and Practice in Sleep Medicine</SO>
<YR>1994</YR>
<PG>437-52</PG>
<ED>Kryger MH, Roth T, Dement W</ED>
<PB>WB Saunders</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Widmalm-1995" NAME="Widmalm 1995" TYPE="JOURNAL_ARTICLE">
<AU>Widmalm SE, Christensen RL, Gunn SM</AU>
<TI>Oral parafunction as temporomandibular disorder risk factors in children</TI>
<SO>Journal Craniomandibular Practice</SO>
<YR>1995</YR>
<VL>13</VL>
<NO>4</NO>
<PG>242-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Winocur-2003" MODIFIED="2014-10-02 22:04:45 +0100" MODIFIED_BY="Anne Lawson" NAME="Winocur 2003" TYPE="JOURNAL_ARTICLE">
<AU>Winocur E, Gavish A, Voikovitch M, Emodi-Perlman A, Eli I</AU>
<TI>Drugs and bruxism: a critical review</TI>
<SO>Journal of Orofacial Pain</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>2</NO>
<PG>99-111</PG>
<IDENTIFIERS MODIFIED="2013-05-21 21:13:46 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="12836498"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-05-21 20:50:43 +0100" MODIFIED_BY="[Empty name]"/>
<PENDING_REFERENCES MODIFIED="2013-05-28 17:01:23 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Saletu-2010a" MODIFIED="2013-05-28 17:01:23 +0100" MODIFIED_BY="[Empty name]" NAME="Saletu 2010a" TYPE="JOURNAL_ARTICLE">
<AU>Saletu A, Parapatics S, Anderer P, Matejka M, Saletu B</AU>
<TI>Controlled clinical, polysomnographic and psychometric studies on differences between sleep bruxers and controls and acute effects of clonazepam as compared with placebo</TI>
<SO>European archives of psychiatry and clinical neuroscience</SO>
<YR>2010</YR>
<VL>260</VL>
<NO>2</NO>
<PG>163-74</PG>
<IDENTIFIERS MODIFIED="2013-05-28 17:01:22 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="19603241"/>
</IDENTIFIERS>
</REFERENCE>
</PENDING_REFERENCES>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-10-02 21:50:30 +0100" MODIFIED_BY="Anne Lawson">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-10-02 21:50:29 +0100" MODIFIED_BY="Anne Lawson" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-10-02 21:50:23 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Etzel-1991">
<CHAR_METHODS MODIFIED="2014-10-02 21:50:23 +0100" MODIFIED_BY="Anne Lawson">
<P>Double-blind, randomized, placebo-controlled, cross-over study</P>
<P>Washout period: 8 days</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-10-02 21:50:23 +0100" MODIFIED_BY="Anne Lawson">
<P>8 participants (1 man and 7 women); mean age: 36.6 years (range 22-47 years); history of nocturnal bruxism characterized by facial pain or restricted mandibular motion on awakening (or both), excessive tooth wear, grinding sounds within the past 2 weeks</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-02 21:50:23 +0100" MODIFIED_BY="Anne Lawson">
<P>Group A: L-tryptophan 50 mg/kg body weight for 8 days, 8 participants</P>
<P>Group B: placebo - lactose (colour and size matched) for 8 days, 8 participants</P>
<P>Order of medication randomly assigned<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-10-02 21:50:23 +0100" MODIFIED_BY="Anne Lawson">
<P>Masseteric EMG activity recorded by portable EMG unit</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-02 21:50:23 +0100" MODIFIED_BY="Anne Lawson">
<P>No information about how washout period was performed. Unsuccessful personal contact with study authors</P>
<P>Generation of allocation sequence and allocation concealment unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-10-02 21:50:24 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Huynh--2006">
<CHAR_METHODS MODIFIED="2014-10-02 21:50:23 +0100" MODIFIED_BY="Anne Lawson">
<P>Double-blind, randomized, controlled, cross-over study</P>
<P>Washout period: 1 week</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-10-02 21:50:23 +0100" MODIFIED_BY="Anne Lawson">
<P>25 adults (11 men, 14 women); mean age: 24.4 years (range 21-31 years)</P>
<P>Inclusion criteria: history of tooth grinding for at least 3 nights/week during the last 6 months associated hypertrophy of masseter muscles or presence of tooth wear (or both)</P>
<P>Exclusion criteria: participants with chronic pain, neurological or psychiatric or sleep disorders and using drugs or medication acting on the central nervous system or cardiac system</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-02 21:50:24 +0100" MODIFIED_BY="Anne Lawson">
<P>Group A: propranolol 120 mg (participants received an oral dose of long-acting drug at 7:00 PM), 10 participants</P>
<P>Group B: placebo, 10 participants</P>
<P>Group C: clonidine 0.3 mg (participants received an oral dose, 1 hour before bedtime), 16 participants</P>
<P>Group D: placebo, 16 participants</P>
<P>Comparing: group A versus group B and group C versus group D</P>
<P>Regimen: each participant spent at least 4 nights at the sleep laboratory (night 1 for habituation, night 2 for sleep diagnosis, nights 3 and 4 for interventions). 1 person participated in both interventions, with an interval period of 6 months</P>
<P>Order of medication randomly assigned</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-28 20:22:50 +0100" MODIFIED_BY="Anne Lawson">
<P>Bruxism episodes per hour; sleep duration; sleep efficiency; micro-arousal index; sleep stages 1, 2, 3, 4 and REM (%); adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-02 21:50:24 +0100" MODIFIED_BY="Anne Lawson">
<P>The following additional data were obtained after personal communication: randomization was done with a computer-generated sequence; sealed opaque envelopes were used for allocation concealment</P>
<P>Allocation concealment: all steps were blinded</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-10-02 21:50:24 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Lavigne-2001">
<CHAR_METHODS MODIFIED="2014-10-02 21:50:24 +0100" MODIFIED_BY="Anne Lawson">
<P>Double-blind, randomized, placebo-controlled, cross-over study</P>
<P>Washout period: 1 week</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-10-02 21:50:24 +0100" MODIFIED_BY="Anne Lawson">
<P>7 adults (5 men, 2 women); mean (± SD) age: 28.4 ± 6.1 years(range 23-39 years)</P>
<P>Inclusion criteria: history of tooth grinding for at least 5 nights/week and polygraphic confirmation of a minimum of 4 episodes of sleep bruxism per hour of sleep and a minimum of 4 episodes with tooth grinding sound</P>
<P>None of the participants had any history of medical, neurological, movement, or psychiatric disorders or was taking medication, or alcohol before or during the trial. No participants smoked or had any dental skeletal abnormalities</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-02 21:50:24 +0100" MODIFIED_BY="Anne Lawson">
<P>Group A: bromocriptine - start dose 1.25 mg to 7.5 mg (6 days to increase up the dose) and 7.5 mg maintained for the next 8 days, 7 participants<BR/>Group B: placebo (capsules had the same colour as bromocriptine), 2 weeks, 7 participants</P>
<P>Domperidone administrated 30 minutes before bromocriptine or placebo to reduce adverse effects</P>
<P>Regimen: each participant spent 4 nights at the sleep laboratory for habituation, sleep diagnosis and interventions</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-10-02 21:50:24 +0100" MODIFIED_BY="Anne Lawson">
<P>Bruxism episodes per hour; bruxism bursts per hour; bruxism bursts per episode; number of episodes with grinding noise; sleep duration (minutes); sleep efficiency (%); sleep stages 1 and 2 (%); sleep stages 3 and 4 (%); REM (%); micro-arousals index; sleep onset latency (minutes); adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-02 21:50:24 +0100" MODIFIED_BY="Anne Lawson">
<P>The following additional information was obtained through personal contact; sealed opaque envelopes were used for allocation concealment</P>
<P>Allocation concealment: all steps were blinded</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-10-02 21:50:26 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Lobbezoo-1997a">
<CHAR_METHODS MODIFIED="2014-10-02 21:50:26 +0100" MODIFIED_BY="Anne Lawson">
<P>Double-blind, randomized, placebo-controlled, cross-over study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-10-02 21:50:26 +0100" MODIFIED_BY="Anne Lawson">
<P>10 adults (5 men, 5 women); mean (± SD) age 27.5 ± 5.4 years (range 19-36 years)</P>
<P>Inclusion criteria: history of tooth grinding sounds during sleep for at least 5 nights/week during the last 6 months reported by partner; tooth wear with a minimum score of 1</P>
<P>Exclusion criteria: participants with neurological or psychiatric or sleep disorders; missing &gt; 2 posterior teeth; presence of distinct orthodontic abnormalities; using illicit drugs, alcohol or medication with a known influence on sleep structure, motor behaviour, and dopamine transmission. Participants who had been treated with physiotherapy for bruxism were also excluded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-02 21:50:26 +0100" MODIFIED_BY="Anne Lawson">
<P>Group A: levodopa100 mg plus benserazide 25 mg to reduce adverse effects, 10 participants<BR/>Group B: placebo. 2 oral doses: the first dose 1 hour before bedtime and the second dose 4 hours after the first dose, 10 participants</P>
<P>Regimen: each participant spent 3 nights at the sleep laboratory for habituation, sleep diagnosis and interventions</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-10-02 21:50:26 +0100" MODIFIED_BY="Anne Lawson">
<P>Bruxism episodes per hour; bruxism bursts per episode; micro-arousals; adverse effects. Sleep variables were analysed by study authors, but not reported in the paper<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-02 21:50:26 +0100" MODIFIED_BY="Anne Lawson">
<P>The following additional information was obtained through personal contact: randomization was done with a computer-generated sequence; sealed opaque envelopes were used for allocation concealment</P>
<P>Allocation concealment; all steps were blinded<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-10-02 21:50:27 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Mohamed-1997">
<CHAR_METHODS MODIFIED="2014-10-02 21:50:26 +0100" MODIFIED_BY="Anne Lawson">
<P>Double-blind, randomized, placebo-controlled, cross-over study</P>
<P>Washout period: 1 week</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-10-02 21:50:27 +0100" MODIFIED_BY="Anne Lawson">
<P>10 adults (2 men, 8 women); mean (177 SD) age: 35 ± 12 years</P>
<P>Inclusion criteria: history of tooth grinding or clenching (or both), presence of some occlusal tooth wear</P>
<P>Exclusion criteria: history of thyroid medications, hyperthyroidism, seizures, glaucoma, urinary retention, diabetes mellitus, hypertension, cardiovascular disorders, hypersensitivity to amitriptyline, participants who were taking medication or alcohol before or during the trial, pregnant and nursing women</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-02 21:50:27 +0100" MODIFIED_BY="Anne Lawson">
<P>Group A: amitriptyline 25 mg/night for 1 week, 10 participants</P>
<P>Group B: placebo 25 mg/night for 1 week, 10 participants</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-10-02 21:50:27 +0100" MODIFIED_BY="Anne Lawson">
<P>Sleep duration (minutes); pain intensity levels; masseteric EMG activity recorded by portable EMG unit; level of anxiety and depression; adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-02 21:50:27 +0100" MODIFIED_BY="Anne Lawson">
<P>Unsuccessful personal contact</P>
<P>Generation of allocation sequence and allocation concealment unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-10-02 21:50:28 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Raigrodski-2001a">
<CHAR_METHODS MODIFIED="2014-10-02 21:50:27 +0100" MODIFIED_BY="Anne Lawson">
<P>Double-blind, randomized, placebo-controlled, cross-over study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-10-02 21:50:27 +0100" MODIFIED_BY="Anne Lawson">
<P>10 women; mean age: 39 years (range 31-54 years)</P>
<P>Inclusion criteria: history of tooth grinding or clenching (or both), presence of some occlusal tooth wear</P>
<P>Exclusion criteria: participants taking thyroid medications; with a history of hyperthyroidism, seizures, glaucoma, urinary retention, diabetes mellitus, hypertension, cardiovascular disorders, and hypersensitivity to amitriptyline; taking medications or alcohol before or during the trial; pregnant and nursing women</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-02 21:50:27 +0100" MODIFIED_BY="Anne Lawson">
<P>Group A: amitriptyline 25 mg/night during 4 weeks, 10 participants</P>
<P>Group B: placebo 25 mg/night during 4 weeks, 10 participants</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-10-02 21:50:28 +0100" MODIFIED_BY="Anne Lawson">
<P>Sleep duration (minutes); masseteric EMG activity recorded by portable EMG unit; adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-02 21:50:28 +0100" MODIFIED_BY="Anne Lawson">
<P>Unsuccessful personal contact</P>
<P>Randomization was done with a computer-generated sequence; unclear allocation concealment</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-10-02 21:50:28 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Raigrodski-2001b">
<CHAR_METHODS MODIFIED="2014-10-02 21:50:28 +0100" MODIFIED_BY="Anne Lawson">
<P>Double-blind, randomized, placebo-controlled, cross-over study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-10-02 21:50:28 +0100" MODIFIED_BY="Anne Lawson">
<P>10 women; aged &#8805; 18 years</P>
<P>Inclusion criteria: history of tooth grinding or clenching (or both), presence of temporomandibular disorder symptoms, such as facial pain or headaches from the jaw muscles or temporomandibular joint (or both)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-02 21:50:28 +0100" MODIFIED_BY="Anne Lawson">
<P>Group A: amitriptyline 25 mg/night for 4 weeks, 10 participants</P>
<P>Group B: placebo 25 mg/night for 4 weeks, 10 participants</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain intensity levels; perception of stress levels</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-02 21:50:28 +0100" MODIFIED_BY="Anne Lawson">
<P>Unsuccessful personal contact</P>
<P>Randomization was done with a computer-generated sequence; allocation concealment unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>EMG: electromyography; PM: post meridian; SD: standard deviation.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-10-02 21:50:29 +0100" MODIFIED_BY="Anne Lawson" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-10-02 21:50:29 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Chasins-1959">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-02 21:50:29 +0100" MODIFIED_BY="Anne Lawson">
<P>Non-randomized clinical study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-10-02 21:50:29 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Guarda_x002d_Nardini-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-02 21:50:29 +0100" MODIFIED_BY="Anne Lawson">
<P>Controlled placebo pilot study. Authors stated "a randomised clinical trial (RCT)-like design was adopted". Unsuccessful personal contact</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-10-02 21:50:29 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Lee-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-02 21:50:29 +0100" MODIFIED_BY="Anne Lawson">
<P>Clinical diagnosis not specified. Unsuccessful personal contact</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-10-02 21:50:29 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Lobbezoo-1997b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-02 21:50:29 +0100" MODIFIED_BY="Anne Lawson">
<P>The trial was interrupted due to adverse effects, only 2 participants (1 in each group) completed the study. Rate of drop-outs 66%</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-10-02 21:50:29 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Reim_x00e3_o-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-02 21:50:29 +0100" MODIFIED_BY="Anne Lawson">
<P>Non-randomized clinical study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-10-02 21:50:29 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Saletu-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-02 21:50:29 +0100" MODIFIED_BY="Anne Lawson">
<P>Non-randomized clinical study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-10-02 21:50:29 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Salute-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-02 21:50:29 +0100" MODIFIED_BY="Anne Lawson">
<P>Non-randomized clinical study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-10-02 21:50:29 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Tan-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-02 21:50:29 +0100" MODIFIED_BY="Anne Lawson">
<P>Non-randomized clinical study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2014-10-02 21:50:30 +0100" MODIFIED_BY="Anne Lawson" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2014-10-02 21:50:30 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Carra-2010">
<CHAR_METHODS MODIFIED="2014-10-02 21:50:30 +0100" MODIFIED_BY="Anne Lawson">
<P>Double-blind, randomized, controlled, cross-over study</P>
<P>Washout period: 1 week</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-10-02 21:50:30 +0100" MODIFIED_BY="Anne Lawson">
<P>16 adults (6 men, 10 women); mean age: 24.5 years (range 21-31 years)</P>
<P>Inclusion criteria: history of tooth-grinding (&gt; 3 nights/week) and clinical signs and symptoms of sleep bruxism (tooth wear, masseter muscle hypertrophy, morning jaw muscle fatigue or tenderness). Sleep bruxism diagnosis was confirmed if participants met the standard polysomnographic research criteria (&gt; 4 episodes of RMMA/hour of sleep) in the second night of sleep recording</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-02 21:50:30 +0100" MODIFIED_BY="Anne Lawson">
<P>Group A: single dose clonidine (0.3 mg/mouth) at bedtime</P>
<P>Group B: placebo at bedtime</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-10-02 21:50:30 +0100" MODIFIED_BY="Anne Lawson">
<P>Sleep stages, sleep arousals and RMMA/sleep bruxism episodes were scored according to standard criteria. CAP was scored according to the published rules. Each CAP phase A was visually detected during NREM sleep on the C3A2 derivation by the use of Somnologica (Embla, Germany), then classified into subtypes A1, A2 or A3. The following CAP parameters were evaluated: total CAP time; CAP rate; number and duration of CAP sequences; number and duration of A phases; number and duration of B phases; and number and per cent of subtypes A1, A2 and A3</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-02 21:50:30 +0100" MODIFIED_BY="Anne Lawson">
<P>The following additional information is pending:</P>
<OL>
<LI>description of the process used for random sequence generation and for allocation concealment</LI>
<LI>description of the exclusion criteria (if any) for the study participants</LI>
<LI>details of outcomes</LI>
</OL>
<P>Allocation concealment: all steps were blinded</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-10-02 21:50:30 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Ghanizadeh-2013">
<CHAR_METHODS MODIFIED="2014-10-02 21:50:30 +0100" MODIFIED_BY="Anne Lawson">
<P>Randomized, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-10-02 21:50:30 +0100" MODIFIED_BY="Anne Lawson">
<P>30 children (14 boys, 16 girls); mean (± SD) age: hydroxyzine 8.4 ± 3.3 years, placebo 6.5 ± 1.5 years. Sleep bruxism was diagnosed according to the classification criteria suggested by the American Academy of Sleep Medicine. Inclusion criteria: parent able to report bruxism; confirmation by a child and adolescent psychiatrist using diagnostic criteria; being able to take oral medication; providing informed parental consent for voluntary participation in this study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-02 21:50:30 +0100" MODIFIED_BY="Anne Lawson">
<P>Group A: hydroxyzine 25-50 mg at night, for 4 weeks</P>
<P>Group B: placebo at night, for 4 weeks</P>
<P>Higher dosage will be given to children older than 8 years of age</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-10-02 21:50:30 +0100" MODIFIED_BY="Anne Lawson">
<P>Severity of sleep bruxism and adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-02 21:50:30 +0100" MODIFIED_BY="Anne Lawson">
<P>The following additional information is pending:</P>
<OL>
<LI>description of the process used for random sequence generation and for allocation concealment</LI>
<LI>details of outcomes</LI>
</OL>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-10-02 21:50:30 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Shim-2014">
<CHAR_METHODS MODIFIED="2014-10-02 21:50:30 +0100" MODIFIED_BY="Anne Lawson">
<P>Clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-10-02 21:50:30 +0100" MODIFIED_BY="Anne Lawson">
<P>20 adults with a clinical diagnosis of sleep bruxism completed this study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-02 21:50:30 +0100" MODIFIED_BY="Anne Lawson">
<P>Group A: bilateral BoNT-A injections (25 U per muscle) into the masseter muscles only, 10 participants Group B: injections into both the masseter and temporalis muscles, 10 participants</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-10-02 21:50:30 +0100" MODIFIED_BY="Anne Lawson">
<P>RMMA and orofacial activity. The peak amplitude of electromyographic activity in the 2 muscles was also measured</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-02 21:50:30 +0100" MODIFIED_BY="Anne Lawson">
<P>The following additional information is pending:</P>
<OL>
<LI>type of study</LI>
<LI>details of outcomes</LI>
<LI>intervention</LI>
</OL>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES>
<P>CAP: cyclic alternating pattern; NREM: non-rapid eye movement; RMMA: rhythmic masticatory muscle activity.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-10-02 21:50:29 +0100" MODIFIED_BY="Anne Lawson">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-10-02 21:50:29 +0100" MODIFIED_BY="Anne Lawson" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-02 21:50:23 +0100" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Etzel-1991">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-28 20:23:33 +0100" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Huynh--2006">
<DESCRIPTION>
<P>Computer generated sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-02 21:50:24 +0100" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Lavigne-2001">
<DESCRIPTION>
<P>Computer-generated sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-02 21:50:26 +0100" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Lobbezoo-1997a">
<DESCRIPTION>
<P>Computer-generated sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-02 21:50:27 +0100" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Mohamed-1997">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-02 21:50:28 +0100" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Raigrodski-2001a">
<DESCRIPTION>
<P>Computer-generated sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-02 21:50:29 +0100" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Raigrodski-2001b">
<DESCRIPTION>
<P>Computer-generated sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-10-02 21:50:29 +0100" MODIFIED_BY="Anne Lawson" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-02 21:50:23 +0100" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Etzel-1991">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-28 20:23:34 +0100" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Huynh--2006">
<DESCRIPTION>
<P>Sealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-02 21:50:24 +0100" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Lavigne-2001">
<DESCRIPTION>
<P>Sealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-02 21:50:26 +0100" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Lobbezoo-1997a">
<DESCRIPTION>
<P>Sealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-02 21:50:27 +0100" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Mohamed-1997">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-02 21:50:28 +0100" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Raigrodski-2001a">
<DESCRIPTION>
<P>Not stated clearly. Randomization list was maintained by an independent party to the end of the clinical portion of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-02 21:50:29 +0100" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Raigrodski-2001b">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2014-10-02 21:50:29 +0100" MODIFIED_BY="Anne Lawson" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-10-02 21:50:23 +0100" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Etzel-1991">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-09-28 20:23:35 +0100" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Huynh--2006">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-10-02 21:50:25 +0100" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Lavigne-2001">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-10-02 21:50:26 +0100" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Lobbezoo-1997a">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-10-02 21:50:27 +0100" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Mohamed-1997">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-10-02 21:50:28 +0100" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Raigrodski-2001a">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-10-02 21:50:29 +0100" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Raigrodski-2001b">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2014-10-02 21:50:29 +0100" MODIFIED_BY="Anne Lawson" NO="9">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-02 21:50:23 +0100" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Etzel-1991">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-28 20:23:35 +0100" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Huynh--2006">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-02 21:50:25 +0100" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Lavigne-2001">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-02 21:50:26 +0100" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Lobbezoo-1997a">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-02 21:50:27 +0100" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Mohamed-1997">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-02 21:50:28 +0100" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Raigrodski-2001a">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-02 21:50:29 +0100" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Raigrodski-2001b">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2014-08-14 19:26:29 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-10-02 21:50:29 +0100" MODIFIED_BY="Anne Lawson" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-10-02 21:50:23 +0100" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Etzel-1991">
<DESCRIPTION>
<P>No drop-outs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-10-02 21:50:24 +0100" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Huynh--2006">
<DESCRIPTION>
<P>No drop-outs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-10-02 21:50:25 +0100" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Lavigne-2001">
<DESCRIPTION>
<P>No drop-outs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-10-02 21:50:26 +0100" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Lobbezoo-1997a">
<DESCRIPTION>
<P>No drop-outs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-10-02 21:50:27 +0100" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Mohamed-1997">
<DESCRIPTION>
<P>No drop-outs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-10-02 21:50:28 +0100" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Raigrodski-2001a">
<DESCRIPTION>
<P>No drop-outs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-10-02 21:50:29 +0100" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Raigrodski-2001b">
<DESCRIPTION>
<P>No drop-outs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2014-10-02 21:50:29 +0100" MODIFIED_BY="Anne Lawson" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-02 21:50:23 +0100" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Etzel-1991">
<DESCRIPTION>
<P>Did not report sounds of tooth grinding and side effects</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-02 21:50:24 +0100" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Huynh--2006">
<DESCRIPTION>
<P>No selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-02 21:50:26 +0100" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Lavigne-2001">
<DESCRIPTION>
<P>No selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-02 21:50:26 +0100" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Lobbezoo-1997a">
<DESCRIPTION>
<P>Did not report washout period; however, study authors stated that that they did not observe any carry-over effects after either experimental condition</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-02 21:50:27 +0100" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Mohamed-1997">
<DESCRIPTION>
<P>Did not report sounds of tooth grinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-02 21:50:28 +0100" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Raigrodski-2001a">
<DESCRIPTION>
<P>Did not report sounds of tooth grinding and washout period</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-02 21:50:29 +0100" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Raigrodski-2001b">
<DESCRIPTION>
<P>Did not report sounds of tooth grinding, side effects and washout period</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-08-14 19:26:29 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2014-08-14 19:12:55 +0100" MODIFIED_BY="[Empty name]" NO="10">
<NAME>New Item</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-10-03 13:14:33 +0100" MODIFIED_BY="Anne Lawson">
<COMPARISON ID="CMP-001" MODIFIED="2014-10-02 21:54:32 +0100" MODIFIED_BY="Anne Lawson" NO="1">
<NAME>Amitriptyline (25 mg) versus placebo</NAME>
<CONT_OUTCOME CHI2="0.08441766482046965" CI_END="0.3409566860202076" CI_START="-0.9071624540013985" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.2831028839905954" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2014-10-02 21:54:32 +0100" MODIFIED_BY="Anne Lawson" NO="1" P_CHI2="0.7713976728888974" P_Q="1.0" P_Z="0.37393204669675006" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" UNITS="" WEIGHT="100.0" Z="0.889132196997448">
<NAME>Masseteric electromyography activity per minute</NAME>
<GROUP_LABEL_1>Amitriptyline</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours a
mitriptyline
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p
lacebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.6876819243998642" CI_START="-1.0703511660947989" EFFECT_SIZE="-0.19133462084746736" ESTIMABLE="YES" MEAN_1="755.64" MEAN_2="1125.53" ORDER="1" SD_1="1119.03" SD_2="2367.29" SE="0.44848607024460746" STUDY_ID="STD-Mohamed-1997" TOTAL_1="10" TOTAL_2="10" WEIGHT="50.40318676313956"/>
<CONT_DATA CI_END="0.5097703439670997" CI_START="-1.2624966806808964" EFFECT_SIZE="-0.37636316835689837" ESTIMABLE="YES" MEAN_1="206.69" MEAN_2="371.95" ORDER="2" SD_1="284.22" SD_2="522.43" SE="0.45211724261961245" STUDY_ID="STD-Raigrodski-2001a" TOTAL_1="10" TOTAL_2="10" WEIGHT="49.59681323686044"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.3593939897186601" CI_END="0.44809128519120955" CI_START="-1.7241792427372755" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.638043978773033" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2014-09-28 21:57:06 +0100" MODIFIED_BY="Anne Lawson" NO="2" P_CHI2="0.5488432278930275" P_Q="1.0" P_Z="0.24958019861280367" Q="0.0" RANDOM="NO" SCALE="56.97" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" UNITS="" WEIGHT="100.0" Z="1.1513696870346284">
<NAME>Pain intensity</NAME>
<GROUP_LABEL_1>Amitriptyline</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours a
mitriptyline
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p
lacebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.597405593683229" CI_START="-1.9974055936832285" EFFECT_SIZE="-0.19999999999999973" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="2.3" ORDER="3" SD_1="2.0" SD_2="2.1" SE="0.91706052144883" STUDY_ID="STD-Mohamed-1997" TOTAL_1="10" TOTAL_2="10" WEIGHT="36.51536539521261"/>
<CONT_DATA CI_END="0.4731686892436935" CI_START="-2.2531686892436937" EFFECT_SIZE="-0.8900000000000001" ESTIMABLE="YES" MEAN_1="1.96" MEAN_2="2.85" ORDER="4" SD_1="1.53" SD_2="1.58" SE="0.6955070093104742" STUDY_ID="STD-Raigrodski-2001b" TOTAL_1="10" TOTAL_2="10" WEIGHT="63.484634604787395"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.1321056494446813" CI_END="59.857994289575814" CI_START="-9.117784983116596" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="25.370104653229607" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2014-09-28 21:57:22 +0100" MODIFIED_BY="Anne Lawson" NO="3" P_CHI2="0.7162588307997362" P_Q="1.0" P_Z="0.1493600128281265" Q="0.0" RANDOM="NO" SCALE="582.67" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" UNITS="" WEIGHT="100.0" Z="1.4417957123110912">
<NAME>Sleep duration</NAME>
<GROUP_LABEL_1>Amitriptyline</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours p
lacebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours a
mitriptyline
</GRAPH_LABEL_2>
<CONT_DATA CI_END="70.6205617411704" CI_START="-34.620561741170405" EFFECT_SIZE="18.0" ESTIMABLE="YES" MEAN_1="481.0" MEAN_2="463.0" ORDER="5" SD_1="62.0" SD_2="58.0" SE="26.847718711279736" STUDY_ID="STD-Mohamed-1997" TOTAL_1="10" TOTAL_2="10" WEIGHT="42.95584633723193"/>
<CONT_DATA CI_END="76.58264344613974" CI_START="-14.742643446139816" EFFECT_SIZE="30.91999999999996" ESTIMABLE="YES" MEAN_1="430.83" MEAN_2="399.91" ORDER="6" SD_1="65.38" SD_2="33.96" SE="23.297695164972865" STUDY_ID="STD-Raigrodski-2001a" TOTAL_1="10" TOTAL_2="10" WEIGHT="57.04415366276806"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.6913646001441411" CI_START="-3.151364600144141" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.23" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2014-09-28 21:57:43 +0100" MODIFIED_BY="Anne Lawson" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.20958401759854373" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="100.0" Z="1.254710168389389">
<NAME>Perception of stress levels</NAME>
<GROUP_LABEL_1>Amitriptyline</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours a
mitriptyline
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p
lacebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.6913646001441411" CI_START="-3.151364600144141" EFFECT_SIZE="-1.23" ESTIMABLE="YES" MEAN_1="2.23" MEAN_2="3.46" ORDER="7" SD_1="1.86" SD_2="2.48" SE="0.9803060746521977" STUDY_ID="STD-Raigrodski-2001b" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2014-10-03 13:14:33 +0100" MODIFIED_BY="Anne Lawson" NO="2">
<NAME>Bromocriptine (7.5 mg) versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.125694501782729" CI_START="-2.92569450178273" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5999999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2014-09-28 21:58:34 +0100" MODIFIED_BY="Anne Lawson" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.7387227953504567" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="7" TOTAL_2="7" UNITS="" WEIGHT="100.0" Z="0.3335451753206102">
<NAME>Bruxism episodes per hour</NAME>
<GROUP_LABEL_1>Bromocriptine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours b
romocriptine
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p
lacebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.125694501782729" CI_START="-2.92569450178273" EFFECT_SIZE="0.5999999999999996" ESTIMABLE="YES" MEAN_1="9.6" MEAN_2="9.0" ORDER="8" SD_1="3.96" SD_2="2.64" SE="1.7988567798148118" STUDY_ID="STD-Lavigne-2001" TOTAL_1="7" TOTAL_2="7" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="49.46510779467347" CI_START="-53.46510779467347" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2014-10-03 13:14:33 +0100" MODIFIED_BY="Anne Lawson" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.9392864668587892" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="7" TOTAL_2="7" UNITS="" WEIGHT="100.0" Z="0.07616671055502602">
<NAME>Bruxism bursts per hour</NAME>
<GROUP_LABEL_1>Favours b
romocriptine
</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours b
romocriptine
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p
lacebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="49.46510779467347" CI_START="-53.46510779467347" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="76.9" MEAN_2="78.9" ORDER="9" SD_1="43.56" SD_2="54.12" SE="26.258190558920305" STUDY_ID="STD-Lavigne-2001" TOTAL_1="7" TOTAL_2="7" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.8506731213958134" CI_START="-1.8506731213958134" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.03" MODIFIED="2014-09-28 21:59:40 +0100" MODIFIED_BY="Anne Lawson" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.6767557966176294" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="7" TOTAL_2="7" UNITS="" WEIGHT="100.0" Z="0.4168942007930565">
<NAME>Bursts per episode</NAME>
<GROUP_LABEL_1>Bromocriptine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours b
romocriptine
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p
lacebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.8506731213958134" CI_START="-1.8506731213958134" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="7.4" MEAN_2="6.9" ORDER="10" SD_1="2.37" SD_2="2.11" SE="1.1993450593672246" STUDY_ID="STD-Lavigne-2001" TOTAL_1="7" TOTAL_2="7" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="28.799033186140356" CI_START="-23.999033186140352" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.400000000000002" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2014-09-28 22:00:18 +0100" MODIFIED_BY="Anne Lawson" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.8585776349837022" Q="0.0" RANDOM="NO" SCALE="516.86" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="7" TOTAL_2="7" UNITS="" WEIGHT="100.0" Z="0.1781850694958676">
<NAME>Number of episodes with grinding noise</NAME>
<GROUP_LABEL_1>Bromocriptine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours b
romocriptine
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p
lacebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="28.799033186140356" CI_START="-23.999033186140352" EFFECT_SIZE="2.400000000000002" ESTIMABLE="YES" MEAN_1="30.3" MEAN_2="27.9" ORDER="11" SD_1="21.38" SD_2="28.51" SE="13.469141981369331" STUDY_ID="STD-Lavigne-2001" TOTAL_1="7" TOTAL_2="7" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.086655039765163E-33" CI_END="58.60833302581051" CI_START="-47.00833302581049" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="5.8000000000000105" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-002.05" MODIFIED="2014-09-28 22:00:40 +0100" MODIFIED_BY="Anne Lawson" NO="5" P_CHI2="0.0" P_Q="1.0" P_Z="0.8295606377714959" Q="0.0" RANDOM="NO" SCALE="826.9" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="7" TOTAL_2="7" UNITS="" WEIGHT="100.00000000000001" Z="0.2152651003919445">
<NAME>Sleep duration (minutes)</NAME>
<GROUP_LABEL_1>Bromocriptine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 
placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours b
romocriptine
</GRAPH_LABEL_2>
<CONT_DATA CI_END="58.60833302581051" CI_START="-47.00833302581049" EFFECT_SIZE="5.800000000000011" ESTIMABLE="YES" MEAN_1="431.6" MEAN_2="425.8" ORDER="12" SD_1="35.11" SD_2="62.04" SE="26.943522147527144" STUDY_ID="STD-Lavigne-2001" TOTAL_1="7" TOTAL_2="7" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="5.391987787874891" CI_START="-5.391987787874891" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2014-09-28 22:01:02 +0100" MODIFIED_BY="Anne Lawson" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="7" TOTAL_2="7" UNITS="" WEIGHT="100.0" Z="0.0">
<NAME>Sleep efficiency (%)</NAME>
<GROUP_LABEL_1>Bromocriptine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours p
lacebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours b
romocriptine
</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.391987787874891" CI_START="-5.391987787874891" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="93.9" MEAN_2="93.9" ORDER="13" SD_1="5.01" SD_2="5.28" SE="2.7510647289471657" STUDY_ID="STD-Lavigne-2001" TOTAL_1="7" TOTAL_2="7" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="13.196754985516796" CI_START="-3.3967549855168127" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="4.8999999999999915" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.07" MODIFIED="2014-09-28 22:01:22 +0100" MODIFIED_BY="Anne Lawson" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.24705193689401295" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="7" TOTAL_2="7" UNITS="" WEIGHT="100.0" Z="1.157539729811369">
<NAME>Stages 1 
and 2 (%)</NAME>
<GROUP_LABEL_1>Bromocriptine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours p
lacebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours b
romocriptine
</GRAPH_LABEL_2>
<CONT_DATA CI_END="13.196754985516796" CI_START="-3.3967549855168127" EFFECT_SIZE="4.8999999999999915" ESTIMABLE="YES" MEAN_1="69.8" MEAN_2="64.9" ORDER="14" SD_1="7.65" SD_2="8.18" SE="4.233116042417385" STUDY_ID="STD-Lavigne-2001" TOTAL_1="7" TOTAL_2="7" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.303015347916863" CI_START="-9.303015347916862" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.08" MODIFIED="2014-09-28 22:01:45 +0100" MODIFIED_BY="Anne Lawson" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.47136763638742485" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="7" TOTAL_2="7" UNITS="" WEIGHT="100.0" Z="0.7202556088382965">
<NAME>Stages 3 
and 4 (%)</NAME>
<GROUP_LABEL_1>Bromocriptine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours p
lacebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours b
romocriptine
</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.303015347916863" CI_START="-9.303015347916862" EFFECT_SIZE="-2.5" ESTIMABLE="YES" MEAN_1="12.9" MEAN_2="15.4" ORDER="15" SD_1="5.8" SD_2="7.12" SE="3.4709899781721396" STUDY_ID="STD-Lavigne-2001" TOTAL_1="7" TOTAL_2="7" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.3360671321131448" CI_START="-5.936067132113147" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.3000000000000007" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.09" MODIFIED="2014-09-29 18:12:59 +0100" MODIFIED_BY="Anne Lawson" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.2150574266371691" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="7" TOTAL_2="7" UNITS="" WEIGHT="100.00000000000001" Z="1.2397783100947024">
<NAME>Stages of rapid eye movement
 (REM)
 (%)
</NAME>
<GROUP_LABEL_1>Bromocriptine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 
placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours b
romocriptine
</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.3360671321131448" CI_START="-5.936067132113147" EFFECT_SIZE="-2.3000000000000007" ESTIMABLE="YES" MEAN_1="17.2" MEAN_2="19.5" ORDER="16" SD_1="3.96" SD_2="2.9" SE="1.8551703810855602" STUDY_ID="STD-Lavigne-2001" TOTAL_1="7" TOTAL_2="7" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.8503560119302485" CI_START="-2.250356011930247" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.8000000000000007" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.10" MODIFIED="2014-09-28 22:03:13 +0100" MODIFIED_BY="Anne Lawson" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.6072317777156089" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="7" TOTAL_2="7" UNITS="" WEIGHT="100.0" Z="0.5140289138381069">
<NAME>Micro-arousals index</NAME>
<GROUP_LABEL_1>Bromocriptine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours b
romocriptine
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p
lacebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.8503560119302485" CI_START="-2.250356011930247" EFFECT_SIZE="0.8000000000000007" ESTIMABLE="YES" MEAN_1="9.8" MEAN_2="9.0" ORDER="17" SD_1="3.16" SD_2="2.64" SE="1.5563326856978326" STUDY_ID="STD-Lavigne-2001" TOTAL_1="7" TOTAL_2="7" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.523406830095672" CI_START="-12.523406830095672" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.11" MODIFIED="2014-09-28 22:04:37 +0100" MODIFIED_BY="Anne Lawson" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.27165318411508366" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="7" TOTAL_2="7" UNITS="" WEIGHT="100.0" Z="1.0992634571822">
<NAME>Sleep onset latency (minutes)</NAME>
<GROUP_LABEL_1>Bromocriptine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours b
romocriptine
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p
lacebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.523406830095672" CI_START="-12.523406830095672" EFFECT_SIZE="-4.5" ESTIMABLE="YES" MEAN_1="9.2" MEAN_2="13.7" ORDER="18" SD_1="6.07" SD_2="8.97" SE="4.0936501350959915" STUDY_ID="STD-Lavigne-2001" TOTAL_1="7" TOTAL_2="7" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2014-09-28 22:12:20 +0100" MODIFIED_BY="Anne Lawson" NO="3">
<NAME>Clonidine (0.3 mg) versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.017271182480148806" CI_START="-4.8372711824801495" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.41" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" MODIFIED="2014-09-28 22:05:04 +0100" MODIFIED_BY="Anne Lawson" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.05165258781458509" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="1.946017913793677">
<NAME>Bruxism episodes per hour</NAME>
<GROUP_LABEL_1>Clonidine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours c
lonidine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p
lacebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.017271182480148806" CI_START="-4.8372711824801495" EFFECT_SIZE="-2.41" ESTIMABLE="YES" MEAN_1="3.7" MEAN_2="6.11" ORDER="27" SD_1="3.64" SD_2="3.36" SE="1.2384264209067892" STUDY_ID="STD-Huynh--2006" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="21.060100213285992" CI_START="-15.260100213286037" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.8999999999999773" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2014-09-28 22:05:23 +0100" MODIFIED_BY="Anne Lawson" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.7542896912861794" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="0.3129881161673187">
<NAME>Sleep duration (minutes)</NAME>
<GROUP_LABEL_1>Clonidine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours p
lacebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours c
lonidine</GRAPH_LABEL_2>
<CONT_DATA CI_END="21.060100213285992" CI_START="-15.260100213286037" EFFECT_SIZE="2.8999999999999773" ESTIMABLE="YES" MEAN_1="462.7" MEAN_2="459.8" ORDER="19" SD_1="25.6" SD_2="26.8" SE="9.265527507918803" STUDY_ID="STD-Huynh--2006" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.4179064274479476" CI_START="-1.6179064274479646" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.3999999999999915" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.03" MODIFIED="2014-09-28 22:05:40 +0100" MODIFIED_BY="Anne Lawson" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.6976354413438975" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="0.3885143449428974">
<NAME>Sleep efficiency (%)</NAME>
<GROUP_LABEL_1>Clonidine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 
placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours c
lonidine</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.4179064274479476" CI_START="-1.6179064274479646" EFFECT_SIZE="0.3999999999999915" ESTIMABLE="YES" MEAN_1="95.6" MEAN_2="95.2" ORDER="20" SD_1="2.0" SD_2="3.6" SE="1.0295630140987" STUDY_ID="STD-Huynh--2006" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.7834702943369183" CI_START="-1.383470294336918" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.7000000000000002" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.04" MODIFIED="2014-09-28 22:06:10 +0100" MODIFIED_BY="Anne Lawson" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.5102139412536314" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="0.6585046078685182">
<NAME>Micro-arousal 
index</NAME>
<GROUP_LABEL_1>Clonidine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours c
lonidine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p
lacebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.7834702943369183" CI_START="-1.383470294336918" EFFECT_SIZE="0.7000000000000002" ESTIMABLE="YES" MEAN_1="7.3" MEAN_2="6.6" ORDER="21" SD_1="3.2" SD_2="2.8" SE="1.063014581273465" STUDY_ID="STD-Huynh--2006" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.4630845892196134" CI_START="-1.8630845892196137" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.05" MODIFIED="2014-09-28 22:06:26 +0100" MODIFIED_BY="Anne Lawson" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.813663715962916" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="0.23570226039551606">
<NAME>Sleep 
stage 1 (%)</NAME>
<GROUP_LABEL_1>Clonidine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours p
lacebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours c
lonidine</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.4630845892196134" CI_START="-1.8630845892196137" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="6.5" MEAN_2="6.7" ORDER="22" SD_1="2.4" SD_2="2.4" SE="0.848528137423857" STUDY_ID="STD-Huynh--2006" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="24.44056926533254" CI_START="16.35943073466744" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="20.39999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.06" MODIFIED="2014-09-28 22:11:22 +0100" MODIFIED_BY="Anne Lawson" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="4.3563146431760883E-23" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="9.89545350148238">
<NAME>Sleep 
stage 2 (%)</NAME>
<GROUP_LABEL_1>Clonidine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours p
lacebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours c
lonidine</GRAPH_LABEL_2>
<CONT_DATA CI_END="24.44056926533254" CI_START="16.35943073466744" EFFECT_SIZE="20.39999999999999" ESTIMABLE="YES" MEAN_1="86.8" MEAN_2="66.4" ORDER="23" SD_1="6.4" SD_2="5.2" SE="2.0615528128088303" STUDY_ID="STD-Huynh--2006" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.934702769251957" CI_START="-2.5347027692519566" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.07" MODIFIED="2014-09-28 22:11:39 +0100" MODIFIED_BY="Anne Lawson" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.7924600888840038" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="99.99999999999999" Z="0.26311740579210857">
<NAME>Sleep s
tage 3 (%)</NAME>
<GROUP_LABEL_1>Clonidine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours p
lacebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours c
lonidine</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.934702769251957" CI_START="-2.5347027692519566" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="4.5" ORDER="24" SD_1="2.8" SD_2="3.6" SE="1.140175425099138" STUDY_ID="STD-Huynh--2006" TOTAL_1="16" TOTAL_2="16" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.22670025772875" CI_START="-2.42670025772875" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.08" MODIFIED="2014-09-28 22:11:53 +0100" MODIFIED_BY="Anne Lawson" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.7815112953230714" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="0.27735009811261446">
<NAME>Sleep s
tage 4 (%)</NAME>
<GROUP_LABEL_1>Clonidine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours p
lacebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours c
lonidine</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.22670025772875" CI_START="-2.42670025772875" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="2.1" ORDER="25" SD_1="4.8" SD_2="3.2" SE="1.4422205101855958" STUDY_ID="STD-Huynh--2006" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-18.32517712631114" CI_START="-21.874822873688863" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-20.1" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.09" MODIFIED="2014-09-28 22:12:20 +0100" MODIFIED_BY="Anne Lawson" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="22.196736741044155">
<NAME>Sleep s
tage rapid eye movement (REM) (%)</NAME>
<GROUP_LABEL_1>Clonidine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours p
lacebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 
clonidine</GRAPH_LABEL_2>
<CONT_DATA CI_END="-18.32517712631114" CI_START="-21.874822873688863" EFFECT_SIZE="-20.1" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="20.3" ORDER="26" SD_1="0.4" SD_2="3.6" SE="0.9055385138137417" STUDY_ID="STD-Huynh--2006" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2014-10-02 21:53:20 +0100" MODIFIED_BY="Anne Lawson" NO="4">
<NAME>Propranolol (120 mg) versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.211821900238103" CI_START="-1.8918219002381043" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.1599999999999993" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.01" MODIFIED="2014-09-28 22:13:16 +0100" MODIFIED_BY="Anne Lawson" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.4562814507037918" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="100.0" Z="0.7449839133433961">
<NAME>Bruxism episodes per hour</NAME>
<GROUP_LABEL_1>Propranolol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours p
ropranolol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p
lacebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.211821900238103" CI_START="-1.8918219002381043" EFFECT_SIZE="1.1599999999999993" ESTIMABLE="YES" MEAN_1="6.52" MEAN_2="5.36" ORDER="36" SD_1="4.61" SD_2="1.73" SE="1.557080601638849" STUDY_ID="STD-Huynh--2006" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="16.232681135150145" CI_START="-50.43268113515019" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-17.100000000000023" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.02" MODIFIED="2014-10-02 21:53:05 +0100" MODIFIED_BY="Anne Lawson" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.3146652125347331" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="100.0" Z="1.0054811972593511">
<NAME>Sleep duration (minutes)</NAME>
<GROUP_LABEL_1>Propranolol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours p
lacebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p
ropranolol</GRAPH_LABEL_2>
<CONT_DATA CI_END="16.232681135150145" CI_START="-50.43268113515019" EFFECT_SIZE="-17.100000000000023" ESTIMABLE="YES" MEAN_1="412.0" MEAN_2="429.1" ORDER="28" SD_1="33.49" SD_2="42.08" SE="17.006782470532162" STUDY_ID="STD-Huynh--2006" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="5.805309135797832" CI_START="-7.205309135797838" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7000000000000028" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.03" MODIFIED="2014-10-02 21:53:20 +0100" MODIFIED_BY="Anne Lawson" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.8329646934074424" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="100.0" Z="0.21090078281264946">
<NAME>Sleep efficiency (%)</NAME>
<GROUP_LABEL_1>Propranolol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours p
lacebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p
ropranolol</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.805309135797832" CI_START="-7.205309135797838" EFFECT_SIZE="-0.7000000000000028" ESTIMABLE="YES" MEAN_1="92.0" MEAN_2="92.7" ORDER="29" SD_1="7.58" SD_2="7.26" SE="3.319096262538946" STUDY_ID="STD-Huynh--2006" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="6.663153294160967" CI_START="-4.463153294160968" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.0999999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.04" MODIFIED="2014-09-28 22:14:09 +0100" MODIFIED_BY="Anne Lawson" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.6983543562451571" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="100.0" Z="0.38754286804516686">
<NAME>Micro-arousal index (%)</NAME>
<GROUP_LABEL_1>Propranolol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours p
ropranolol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p
lacebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.663153294160967" CI_START="-4.463153294160968" EFFECT_SIZE="1.0999999999999996" ESTIMABLE="YES" MEAN_1="10.6" MEAN_2="9.5" ORDER="30" SD_1="6.95" SD_2="5.68" SE="2.838395673615643" STUDY_ID="STD-Huynh--2006" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.779177788092846" CI_START="-2.779177788092846" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.05" MODIFIED="2014-09-28 22:14:21 +0100" MODIFIED_BY="Anne Lawson" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="100.0" Z="0.0">
<NAME>Sleep stage 1 (%)</NAME>
<GROUP_LABEL_1>Propranolol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours p
lacebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p
ropranolol</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.779177788092846" CI_START="-2.779177788092846" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="6.3" MEAN_2="6.3" ORDER="31" SD_1="2.84" SD_2="3.47" SE="1.4179739066710642" STUDY_ID="STD-Huynh--2006" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.230589739455687" CI_START="-7.830589739455696" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.8000000000000043" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.06" MODIFIED="2014-09-28 22:14:34 +0100" MODIFIED_BY="Anne Lawson" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.5585432403270367" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="100.0" Z="0.5850066618012935">
<NAME>Sleep stage 2 (%)</NAME>
<GROUP_LABEL_1>Propranolol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours p
lacebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p
ropranolol</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.230589739455687" CI_START="-7.830589739455696" EFFECT_SIZE="-1.8000000000000043" ESTIMABLE="YES" MEAN_1="57.3" MEAN_2="59.1" ORDER="32" SD_1="5.68" SD_2="7.9" SE="3.076888038262036" STUDY_ID="STD-Huynh--2006" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.989324015237492" CI_START="-0.989324015237492" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.07" MODIFIED="2014-09-28 22:14:47 +0100" MODIFIED_BY="Anne Lawson" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.23759407655622977" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="100.0" Z="1.1810218191020017">
<NAME>Sleep stage 3 (%)</NAME>
<GROUP_LABEL_1>Propranolol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours p
lacebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p
ropranolol</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.989324015237492" CI_START="-0.989324015237492" EFFECT_SIZE="1.5" ESTIMABLE="YES" MEAN_1="9.0" MEAN_2="7.5" ORDER="33" SD_1="2.84" SD_2="2.84" SE="1.2700866112198805" STUDY_ID="STD-Huynh--2006" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.873755791806953" CI_START="-3.2737557918069538" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.7999999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.08" MODIFIED="2014-09-28 22:15:41 +0100" MODIFIED_BY="Anne Lawson" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.700314674437144" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="100.0" Z="0.3848957246739021">
<NAME>Sleep stage 4 (%)</NAME>
<GROUP_LABEL_1>Propranolol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours p
lacebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p
ropranolol</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.873755791806953" CI_START="-3.2737557918069538" EFFECT_SIZE="0.7999999999999998" ESTIMABLE="YES" MEAN_1="5.3" MEAN_2="4.5" ORDER="34" SD_1="3.79" SD_2="5.37" SE="2.0784850252046563" STUDY_ID="STD-Huynh--2006" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="5.016523975977887" CI_START="-6.016523975977887" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.09" MODIFIED="2014-09-29 18:12:47 +0100" MODIFIED_BY="Anne Lawson" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.859001911244877" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="100.0" Z="0.1776448351420988">
<NAME>Sleep s
tage rapid eye m
o
vement (REM)
 (%)
</NAME>
<GROUP_LABEL_1>Propranolol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours p
lacebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p
ropranolol</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.016523975977886" CI_START="-6.016523975977886" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="22.1" MEAN_2="22.6" ORDER="35" SD_1="7.9" SD_2="4.1" SE="2.8146047679914137" STUDY_ID="STD-Huynh--2006" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2014-09-28 22:17:03 +0100" MODIFIED_BY="Anne Lawson" NO="5">
<NAME>Tryptophan versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.0576974152489909" CI_START="-0.903235684103039" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.07723086557297598" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.01" MODIFIED="2014-09-28 22:17:03 +0100" MODIFIED_BY="Anne Lawson" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.8773058691809118" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="8" TOTAL_2="8" UNITS="" WEIGHT="100.0" Z="0.15438539445114763">
<NAME>Masseteric 
electromyography activity per second</NAME>
<GROUP_LABEL_1>Tryptophan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours t
ryptophan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p
lacebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.0576974152489909" CI_START="-0.903235684103039" EFFECT_SIZE="0.07723086557297598" ESTIMABLE="YES" MEAN_1="9640.0" MEAN_2="9108.0" ORDER="37" SD_1="6660.0" SD_2="6362.0" SE="0.5002472277091875" STUDY_ID="STD-Etzel-1991" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2014-09-28 22:18:22 +0100" MODIFIED_BY="Anne Lawson" NO="6">
<NAME>Levodopa (Prolopa® 100 mg) versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.701459657476788" CI_START="-3.6414596574767892" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.4700000000000006" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.01" MODIFIED="2014-09-28 22:18:01 +0100" MODIFIED_BY="Anne Lawson" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.18456656373464786" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="100.0" Z="1.3268250447819698">
<NAME>Bruxism episodes per hour</NAME>
<GROUP_LABEL_1>Levodopa</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 
levodopa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p
lacebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.701459657476788" CI_START="-3.6414596574767892" EFFECT_SIZE="-1.4700000000000006" ESTIMABLE="YES" MEAN_1="5.56" MEAN_2="7.03" ORDER="38" SD_1="1.89" SD_2="2.95" SE="1.1079079384136572" STUDY_ID="STD-Lobbezoo-1997a" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.880351793162334E-35" CI_END="2.594052284239714" CI_START="-2.474052284239713" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.06000000000000049" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-006.02" MODIFIED="2014-09-28 22:17:49 +0100" MODIFIED_BY="Anne Lawson" NO="2" P_CHI2="0.0" P_Q="1.0" P_Z="0.9629858338296416" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="100.0" Z="0.04640702948545786">
<NAME>Bruxism bursts per episode</NAME>
<GROUP_LABEL_1>Levodopa</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 
levodopa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p
lacebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.594052284239714" CI_START="-2.474052284239713" EFFECT_SIZE="0.0600000000000005" ESTIMABLE="YES" MEAN_1="9.5" MEAN_2="9.44" ORDER="39" SD_1="3.31" SD_2="2.4" SE="1.29290757596976" STUDY_ID="STD-Lobbezoo-1997a" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.31491810595199" CI_START="-2.9149181059519913" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.3000000000000007" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.03" MODIFIED="2014-09-28 22:18:22 +0100" MODIFIED_BY="Anne Lawson" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.822088571738995" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="100.0" Z="0.22485950669875895">
<NAME>Micro-arousal 
index</NAME>
<GROUP_LABEL_1>Levodopa</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours l
evodopa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p
lacebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.31491810595199" CI_START="-2.9149181059519913" EFFECT_SIZE="-0.3000000000000007" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="10.3" ORDER="40" SD_1="2.2" SD_2="3.6" SE="1.3341664064126335" STUDY_ID="STD-Lobbezoo-1997a" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-10-03 13:15:37 +0100" MODIFIED_BY="Anne Lawson">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-10-03 13:15:37 +0100" MODIFIED_BY="Anne Lawson" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAJtCAYAAAAcrvarAAA9V0lEQVR42u2dD4QVa9zHL0mSJJIr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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-10-02 21:50:30 +0100" MODIFIED_BY="Anne Lawson" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAS8AAAInCAIAAABGB0h/AAAZAElEQVR42u3dv24k1RLH8ZGQEIED
B/sEPIMjZBFBxDuxoQMkNty3QDwCYiFcNiJDgI1YBxt4IePPqu/4+urKsntmunv6nK46/flpdLWa
9a09tOvbVXX6dNVmQ0Rx1BHR0kIjERqJCI1EaCQiNBKhkYjQSIRGIkIjERpplR7jFBcaaXFfGfIl
oZHKOsrkvyU0EqGR1hEkeQ4aKQqKclQ0EhrRSIRGNFJAj4EiGonQSERopKAe43AcGmlxd7n/B56D
RopCIyDRSGhEI5GTcWgkQiMRoZFCJqiGuKCRCI1EhEaK7jHSVDRShOpx/zeERkIjGmnFQPIcNNLy
5aLSEY1EaCQiNBKhkYjQSIRGohEeoxMHGmlxd9n1B0IjoRGNhEY0opGC1I08B41EaCQiNFLM0lHR
iEaKgiIg0UhoRCPRfY+xp4pGIjQSERopdqbKedBIi7mLi4BGap9GIReNtDyQvU64Qs9EIx1VNB7v
PPstrMo50UiERqIdYVDdSDQxWZ0dxRXmqGikY5mZ0XPQiEaKwgwa0UiBmLnviupGonFA8hw0EqGR
qIIvrvhwHBopBDPldmvRSI0XjUXL0dL/FhrpcJxBIxrRuNh1H/LlOoGUqVIIhw7+67DXgkZqPDAS
GqM495rrxv9vooq6aAyBYqLIw1vQiMagRSPnQSMa2/VFXaqwseDVl6Z2JnygkeIAiUY0UqC60WRI
NMZybhfBEw40LpnyrfmtBUJjRBq7PBs5Hm+gEY2B1rzyAg+NjQOZ9AkH50EjoRGNxGOK1Y32VNG4
WITJtadfem2cEI00+g6CRjRSuBy16FkcNFI7NVi6COYsDhpjefaaW1QRGtEISDTSI8/OeCxu9rrR
AXo0hvDplf8inCtAI6ERjZQ/sHdlJo2jEY00jplys43VjWik5WkkNBIa0Ug531qYfcE6/6MxUJwh
QiMaQ18NsZEAuUCm6iwEGsMVjWvuUsUJ0UjySTRSE0DO3hdn5ZCjsakabJHsepbFi7polPWt4mok
agWGRjROWe3sKy/BTK+psD6PRtGgTc+ucwdBo7pxSWa8aYFGajMa9HLeFdutVTcSjQNm3ntHovdO
0LiY59XpFJyuUysa0SjOoBGNmClQ15ma3Gs5/qVA4/JuV2JbdXYavWmBxnXFxhVGgwqZAhqJAkXd
LPEcjVECQpbfQrV+qrNbLj2CEo1NZarxo4HdWjSiMUo0qNPdONGa0dhsyRTf/5I+FXQyjtrMzdLd
QfLdnXlww0Cu/GQcGmnJSkne/qBs9oSD2owGzuKgEY0hogFXQSMaw625aLAtfRYHjZTYS+qEx0In
kxKdgEUjzo+NY8GZQSPFCl9rnvDR5TkPjMblA1eiOJMrnqd7JxON7YfHEu/Re8KBRgoXdUvbXJVz
ojEEPF3aN/RnvA5DvkQjlfXs7C0zwtaN6WpdNKLx2Ex4zXnNvPEcjWhcYzkds9ZFYzt5DlVOrdWN
tEw0yHsHKd0pc5YcFY2iwQyWU5xYKLcVPG+tgcYopWOubogz/lsVnpFm6aCHxhAoposGFWLjCn+D
aGyQRu8KVq7PZ04TsNFYbMzr2d42RmMLd9Y27k2Jsms00sLRwM5TuXiOxnBxoMRJkVwdwbPQOPuE
BTQun6Pu/3IlNGbcebKnKp9sNjbmzXHQSIvVjVAsVEWjkcLdQebiXOd/WkUoiJ/1Jb4f8bOWaCm9
I5KLxkJna0tcZzTS9HI0+AxzHRzpKHcJGw3qX4342TUa1WBNRYPG7qdoRGPVaJCo62T9+XnqRkAu
sOBCJ+NyxXM02hEZ7SiRz4I1kCnM+A+hcRUhN8U51UQ5SKH6HI1oXHLfogKQnnDQ8p6dvYu+szjU
SARr4Gqs8DqjEY0hoq6nr2hsv7rrCr+en/Hdf5kqLRBnUpzA3hPHMq7ZjCqqRGNXcoZ5xky192qY
UUWVYmO6c7D194fQmI8WHcH33ESSTr9CI4nno0N60bseGhP7X5YyLG92PUvgqlfoYqON3YW87zdW
o7Hz9J9q7i6kvkmVSFOz5MBopMajbpdndggaY7n47JZnd5pEzxvTZTdojFIprfwsTokIVnr6UIk7
HRrtWyxPY6E1l54+pG5EY6B9i4x7LdErF2y0tLvQJTyLo/M/GimcL6ZAUef/ZgNjyvu3vsliIyCX
zYG5yv6rITYmvxEmmTBTgcZcXcx1cKSFaewSTozrKk4fkqlS1diYN55X6BKExhaS1a7MqY5ExV7e
p69oFMHaL6RXmCmgsSka65zM9A5H2fsRNpqJjaVPZhaqwQiNbeZmXdrTpCUiWKIZQWikKDVYiby9
6BvSnv5TmzVYG3Na0dhOpqpnXJdqhxmNDfofPQ62RatodSMlzqBairqecFAlIFN3dpMDozFQ0Zji
TYs62KyzxwcaaRXMFF3zXPdBNK4l8AZnxp4qGqMw02V4BRGN+y+1TNXuQiM0dgWecFQ4izOvfTQ2
SGNpINO9ApZlWgEa24yNnnCUq+7Q2HjdmH22dqGbSKI1qxtpsRtH6d3adb5fhsbG4elWv1ubqNZA
Y7how7PRSAuXYSW64yTqTdrl6V5TLgdGY7gdkcg0cpUabLsQLdFYYd+COt2N2y4dU3h8Rm8p2kUa
jRTi9pHCeXQ3pnDYyCe9bUySyYXzyUQ93dGIxhBRN9Eb+vdtDvkSjYCsMWUxy7v/1e5NMtUWqrsu
Sc9CbxurG+0uRMlU0+WTRe9NaETj8nXjLDVSG1U0GtHYlAuiEY0N7gHsScwy7ois8N6ERopyB0nH
+ezvxKGRjmIm41y3QsaPrzjQGMW5s/QsLOfrpZ+RVrs3oVGcyXoHyVs3ohGNgYrGeY+h1Fxz0Soa
jXZEKsWZjNVdMn9wIZqMuvHnhwISjeuisZvvHaLKMy3WloOgMVYZFpZG9XmFYI7GNhOzjN0Q0YhG
ZdL0Zefqz19i2bpUAXIVcSZ+3ahLVctFY9jZSdlpTOYS2Ggy5CZ6JxiNaERj3GQhcq1b6HkPGkP4
X6fjU8JaV2wUwZaJM6Wf/mekcXbLaJRPRsQm+LOTQqfn0YjGNuPMIldDptpC3Zhi3yLpe8zO4tBa
ItgK88lyFwSNaIxCY5Z8cj/taGwhTU30DlGuO0g+l8BGw7fw4HeQChWpzv+0ijww3X975GcnaGzT
I802rnCdPf1vuW5MEWcayCfRSC1kfdX6X6VIE9BISwJZ8/yQ2ca0ZKZadJcSjWlcAhuLR7B0XU9L
d7UIG8HQuIpk0i8i3XWWqfKSdqJB6utsF6fl0nHlnKe7GmikpvyvgTvIjAtGIxrbp7FOanM88GgM
8evskvTt7ortA9vTQmOICJarE0e59y3sPKERjRQlu0FjmzRmPFfgN4jGQImfGixXfY5GWobGvOdR
y+UgaKRlom65V6iqvZwVv6c7GqMUHnk3VCNb7lLtlqGxnT2ARXLgFPlqlh4LaEQjRQESjWgMEWe6
nKfGdTduCsh0KJbz7NktV+j8L1OlKY64QhrT5f9oVMw0TmO+eygPRmOrdWNX8l0ZNFJT6Vm1S+F5
I4UoGk346Aqfxem8w9EeNq5JIhqdU5VMUpSKFI1oXNL/CI2APNZs0dMn8Q+OZ7nrobHBurF0N8Q9
wSGUZWdxaPlMtf4z+hJvM2d5PIhGNC68b4HGx5cajYAMUSmV6+CYqDekdziaKhr9InLl7WIjHfY8
nFerotWNFCukp7CcojpAY7gaLHg0SFdCl3jOUSgHQWNTGVTpJ2x5u6pmuju7EI3VMzWXvVogTVNF
Y6yiMWzHp6IVaaEcBI0N1o2dd7VyBnM0tux/WY6zJKVR3UijaezmO7lWIp+s8Iy0Tnj0DkcLCeqa
J08sdcFjVv5ojJJEzV433v8Fu8h1LKOxHS9JcEykTKaa9Blp521jNDYfz4taTpBRYyNCwInv2Uk7
/3v3nxqMujr/70K9s6dK9T07Y+f/0tdZz7gGM9UUzKgI0LiKCEZJ83Y0orHxeJ6ln6UnHIBcODfL
dSmy3AfRGCjIrHlOsDkIaFQprQXICndS7zdS7diY8W3jZJDz4LZ3RFznFBHYb2t5F/FOcOq83Vmc
BmmMf9vucr5t7HkjLUNjuhlpi1QEYX+DflVRgPRbcD9FIy0cdVPHc2dxSKZ67GUJvU5+vJR/lNhd
oKRXFY0L+8f9HcWiv+N57yCFHv3PbrkcjQ9GvspUG6GxqLuUeE4wexPRQpbLAVlozWgMERsLQVhh
BGJ8Gss9I0UjGkcEATRW/g2iEY1iIxpp1typXNOn4GtO+iTzgSm7ODTid+w6pLlNuxBEaCQiNBKh
kYjQSITG1V5WojHPV9BYikaWWR5rGY28hGU0opFlltGIRpbRiEaWWUYjGllGIxp36d27m7dvL66v
z6+uTn/9dXN5efL69dnNzdN3796EtXzzz83F5cX5q/PT704332xOXpycvTx7+svTN3+vcc3/3Nxc
Xly8Oj//7vT0m83mxcnJy7OzX54+/fvNGzRmovHPP59fXT3Zut3jz9Yd//jjWUDLz39//uT7J1uH
fvzZOvqz39a15t+fP//+yZM+w5stnL89e4bGHDRub/m9nnf/s/2ZUJa3waTXp+9/tj+zkjVvA+Ah
w5vtz6AxOo3bOHDQ+e4+u2JCfcvbCHPQre8+u6JNS2veRsVhhje7ImRiGnedKhq15l0/3DsvpbfN
ae9V2n9Ze6uj+ynZt99uPv5488EHt5/PPtv88MPDJO3ff68Xt7ytu3Yle73p3/VfLa95WyvuSlB7
U9a/rq9bo/H4La/eH97fXLgX++GdF3v/6u3bi/se9uGHtxa+/nrz1Ve3f/joo0EZWmXLF5cXA916
T+7XzJovLy7GGO7PV1ujcf9h3MehbFdYm0zjwR5QvX91fX3em4b99NPtat9//+H3r1+fLW75/NV5
j5fdqc8Bz162vOZX5+ejaHx5drbG2DgEnuFGhsTGCTTebd8/+Pz44+aTT25/BV9++fCvLi9PFrd8
92BguGefvGh5zXcPM4Z/XpyctEbjkLpxXhp7/6FRYzN6/6o3FHz66a3Zzz/v371Y3HK/T9/XIx9s
eM2PeXtywPBmdbHxcTk3cMtn1y7OrhKxRGx8771b4z//3ON8R8bGWSxXjo3B1yw2HgBpCCETtoKG
2Jmrbtz1Ob5uPN5y/box8prVjdNpjFY3PthFvPvcafhT78qWq+2pplizPdUDG6fT9lQjPG/c73/H
PG+c0XK1540p1rz2541J5SxOq2te9VmcxmjsnFPNv2bnVNuhsfvfWwunu99a+CKg5W206d+r/G+y
98XVuta8jZC79le33199MdEyGhegsdv9Rl9vdRTE8q53BXvrrubXvOv9xt5aEY2haWSZZTSikWU0
opFlltGIRpbRiEaWWUYjGllGIz28rERmVImNLIuNxP9YRiMaWUYj8T+W0YhGltFI/I9lNLZEY7nZ
SSzntYzGBWgsNzuJ5dSW0VibxnLvpLOc3TIaq9JYrl8Ly9ktL0zjqC5ssxffw9vDjWokt2cZ5XqZ
sZzd8qppHDsAZ8iXB5dRrs8ny9kth6bxsbvv+qa3deqo/6gjaRx+UyjXA5vl7JZboHH/7JqxcXLC
xLhRmWq5+RAsZ7ccgsYhI6h2TU2clkMOSVmH/Cv7ma88O4nl7JaTxcZoNE6oG0UDltE4dAGlaVQp
sZybxj3zbY6kcf+Orj1Vlu2pHphhOheNuzojeN7I8kqfN5Z7nBh2nU6fsNwIjW3cNZzMZLmR2NhG
DC83O4nl1JbRuEwYLzc7ieW8ltGYLKlmuWHLaOQlLKMRjSyzjEY0soxGNLLMMhrRyDIa10wjkRlV
YiPLYiPxP5bRiEaW0Uj8j2U0opFlNBL/YxmNrdFoKhPLaAxBo6lMLKMxBI3edmcZjSFo1AmG5Sg0
Tv6HSqzw+PZw+y9rb6WhSxrL6WksupJprVMPHjh8/KUOoiwnoPHgEI79fVZ3zag5eEh3Mo2PVzXk
v1R3bZaj0zh8OFy3ey5N7w8MjMmT24qPpdHkCZYzZaoHR27M2Jz/YCI6O42mMrGcKVOdl8aBb5RV
o1E0YDlfpjp7bBy4ntI0qpRYTkPjkHFUB+eZHjNGqjSNdhFZjkXjrknGo8ZRDRnkuH9P9fgZVZ43
srz2GVUxn14OX5vTJyw3NTFu4FPEsHcKJzNZbjA25o3bpjKxjMZAWbSpTCyjMX1Ny3LDltHIS1hG
IxpZZhmNaGQZjWhkmWU0opFlNK6ZRiIzqsRGlsVG4n8soxGNLKOR+B/LaEQjy2gk/scyGluj0VQm
ltEYgkZTmVhGYwgave3OMhpD0KgTDMvz0zj8/zKwe2J9PAa2hxt4pmnIf6AuaSyjsX9gzuM/T2jB
Ouq/WgdRlqvS2Btbuh2diw+Gpj3NV4ePo+qdJzWBxlEDsHTXZrler/FRPfwHdgof0tV78gCceZv8
T4uiJk+wvDyNx0NVjsaDN4shV3Dol6YysZyIxl3d+I+s9/bs4nSHxgoc3AQSG1luPDbOlWHOEtwG
zs9RKbHceN1YiMZRdvbQOCo22kVkuRSNAzc8F99TPfJ5455bT29O6wkby2ucURVZTp+w3P6Mquw0
dk5msozGODR2pjKxjMY4NHamMrGMxjg0sswyGtHIMhrRyDLLaEQjy2hEI8ssoxGNLKORHl5WIjOq
xEaWxUbifyyjEY0so5H4H8toRCPLaCT+xzIaW6Lx3bubt28vrq/Pr65Of/11c3l58vr12c3N03fv
3oS1XG7eU8Y1/3Nzc3lx8er8/LvT0282mxcnJy/Pzn55+vTvN2ZUpaLxzz+fX1092brd48/WHf/4
41lAy+XmPWVc8+/Pn3//5Envm8ZbOH97ZkZVEhq3t/xez7v/2f5MKMvl3nbPuOZtADzYiGP7M2iM
TuM2Dhx0vrvPrphQ33K5TjAZ17yNigNbxu2KkDVoPDi4olqVPPzfKje4qvfLbXV0PyX79tvNxx9v
Pvjg9vPZZ5sffniYpP377/Xilst1Scu45m2tuCtB7U1Z/7q+XozG3qbdYWksOriq98u3by/ue9iH
H94u4OuvN199dfuHjz4alKFVtlyug2jGNV9eXIwx3J+vLk/jwD6rA39yeB/UXS1PCw2u2v/99fV5
bxr200+363z//Yffv359trjlct21M6751fn5KBpfnp0tRmPv/3Yje5Af/MmxTcqHz3U7cnDVwb+6
275/8Pnxx80nn9yu8MsvH/7V5eXJ4pbLTZ7IuOa7hxnDPy9OTtLQODDZmzYVJ+Dgqt5Q8Omnt2Y/
/7x/92Jxy+WmMmVc82PenhwwvMlNY2+r/4M0Dv9/DdnF6aYOrpoQDd5779b4zz/3ON+RsXEWy5Vj
Y/A1rys2ThtWM2HI1DSchticUCnt+hxfNx5vuX7dGHnNyerG/X+YVuwdmakWqhsn0PhgF/Huc6fh
T70rW662p5pizZn2VPf78fAZqUNC60H73aExUl2BwVWjnrDt979jnjfOaLna88YUa07zvJGGXHFn
cbKvOcdZHBp4xZ1Tzb5m51TbobH731sLp7vfWvgioOVy854yrnkbIXftr26/v/rCjKo8NHa73+jr
rY6CWC437ynjmne939hbK6IxNI0ss4xGNLKMRjSyzDIa0cgyGtHIMstoRCPLaKSHl5XIjCqxkWWx
kfgfy2hEI8toJP7HMhrRyDIaif+xjMaWaDTvKfuazahqhEbznrKv2YyqRmj0Hn32NXv3vxEa9ZjJ
vubl++IMP9ozewU8tjXbngE4w0d3jJ23NXDZ5j1lX3OInnHHe2c1Gvf/zDHtz49ftnlP2dccop/q
fhoP9krt7Y/6uG//42V145uyDqR3LKIDO6/uv+LmPWVfc4he43toPNjn+3F4OdhHfNpPjoqlR46j
mjbU0byn7GsOMYdjYN14TM//Uf+vPfFw4GiN0sPhzHtqcs0hZlQdnCi6az7UjDR2eyd+16dxwqRx
856yrzlKbJzm1vPSeEymOu/g1GmZqnlP2dccsW6cMKt42sypuerGg7tQk2kcFRvNe8q+5jR7qt3e
6VR7gCm9p7qr4j3yeeP+AVjmPTW55nZmVK3qxI9zLa2uOfGMquHHd1ZCY+fMZ/41O6faDo2deU/5
12xGVTs0duY95V+zGVXt0Mgyy2hEI8toRCPLLKMRjSyjEY0ss4xGNLKMRnp4WYnMqBIbWRYbif+x
jEY0soxG4n8soxGNLKOR+B/LaGyJRvOesq/ZjKpGaDTvKfuazahqhEbv0Wdfs3f/G6FRj5nsazaj
asTf1plRNe0KmPeUfc1mVEWcUTWNRvOesq/ZjKqIM6r+/6UZVWZUmVG1/Iyqsd3NO/Oe8q/ZjKqI
M6qmzeEw7yn7ms2oijijKsX8RjOqzKgqSOMxmaoZVWZUmVHV7IyqCXWjeU/Z12xGVcQZVdP2VM17
yr5mM6pSyrmWVtdsRlU7NHbOfOZfs3Oq7dDYmfeUf81mVLVDY2feU/41m1HVDo0ss4xGNLKMRjSy
zDIa0cgyGtHIMstoRCPLaKSHl5XIjCqixDdxF4IIjUSERiI0EhEaidBIRGgkykcjEUXQfwD+/aC0
FqW+kgAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-10-02 21:50:30 +0100" MODIFIED_BY="Anne Lawson" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAADnCAMAAAD4paggAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-10-04 00:05:21 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-10-04 00:05:21 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-10-04 00:05:21 +0100" MODIFIED_BY="[Empty name]">Search Strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-10-04 00:05:05 +0100" MODIFIED_BY="[Empty name]">
<P>The subject search used a combination of controlled vocabulary and free text terms based on the strategy for searching MEDLINE via Ovid presented below:</P>
<P>1. randomized controlled trial.pt.</P>
<P>2. (randomized or randomised).ab,ti.</P>
<P>3. placebo.ab,ti.</P>
<P>4. dt.fs.</P>
<P>5. randomly.ab,ti.</P>
<P>6. trial.ab,ti.</P>
<P>7. groups.ab,ti.</P>
<P>8. or/1-7</P>
<P>9. exp animals/</P>
<P>10. exp humans/</P>
<P>11. 9 not (9 and 10)</P>
<P>12. 8 not 11</P>
<P>13. exp Sleep Bruxism/</P>
<P>14. sleep bruxism.tw.</P>
<P>15. exp Bruxism/</P>
<P>16. (bruxis$ or bruxe$).tw.</P>
<P>17. (teeth adj3 grind$).tw.</P>
<P>18. (tooth adj3 grind$).tw.</P>
<P>19. (teeth adj3 clench$).tw.</P>
<P>20. (tooth adj3 clench$).tw.</P>
<P>21. or/13-20</P>
<P>22. exp Pharmaceutical Preparations/</P>
<P>23. exp Antidepressive Agents/</P>
<P>24. exp Anticonvulsants/</P>
<P>25. exp Analgesics/</P>
<P>26. exp Neurotransmitter Agents/</P>
<P>27. (analgesic$ or drug$ or anti?convulsants or antidepressive agent$ or pharmaceutical preparation$ or neurotransmitter$ or dopamin$).tw.</P>
<P>28. exp Adrenergic beta-Antagonists/</P>
<P>29. (adrenergic beta-antagonist or betablocker$ or beta blocker$).tw.</P>
<P>30. exp Muscle Relaxants, Central/</P>
<P>31. muscle relaxant.tw.</P>
<P>32. (botulin$ toxin or clozapin$ or buspirone or gabapentin$ or BTX or BTX A or BTX type A or benzodiazepine or tryptophan or levodopa or l dopa or ldopa or cabergolin$ or pergolid$ or prolopa or clonidin$ or bromocriptin$ or amitriptylin$).tw.</P>
<P>33. or/22-32</P>
<P>34. 12 and 21 and 33</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;7 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;18 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;338 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;50 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;388 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;8 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;320 records excluded and 3 studies are awaiting classification.&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;8 full-text articles excluded, with reasons and 3 awaiting classification.&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>